Data / Research funding / Urologic Diseases
Urologic Diseases: 2,028 NIH awards ($2.4B) to 405 organizations
2,028 NIH awards ($2.4B) in the NIH spending category Urologic Diseases, to 405 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 2,028 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| NCI Early Career Cancer Clinical Investigator Award | NIH | National Cancer Institute | 2021 to 2025 | $65,560,307 | March 10, 1997 | November 30, 2026 | EBERT, BENJAMIN LEVINE | reporter.nih.gov |
| Alliance for Clinical Trials in Oncology Operations Center - GY11 BIQSFP Funded Extension | NIH | National Cancer Institute | 2021 to 2025 | $65,300,792 | April 17, 2014 | February 28, 2026 | PIANTADOSI, STEVEN | reporter.nih.gov |
| Mayo Clinic Comprehensive Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $29,249,641 | April 25, 1997 | August 31, 2030 | WILLMAN, CHERYL LYNN | reporter.nih.gov |
| Comprehensive Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $29,187,201 | March 28, 1997 | March 31, 2027 | SLECKMAN, BARRY P | reporter.nih.gov |
| TO PROVIDE SEQUENCING SERVICES USING WHOLE GENOME SEQUENCING (GERMLINE FFPE) FOR NCI (KLEIN) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $24,069,896 | September 27, 2023 | December 31, 2025 | DOHENY, KIM | reporter.nih.gov |
| Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $16,870,049 | August 4, 1997 | November 30, 2029 | DRAGNEV, KONSTANTIN H. | reporter.nih.gov |
| Pelvic Floor Disorders Network Data Coordinating Center | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $16,166,829 | August 8, 2011 | June 30, 2027 | GANTZ, MARIE G | reporter.nih.gov |
| Center for Pre-Clinical Cancer Research | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $11,277,290 | March 1, 2021 | February 28, 2027 | FRANCIS, JOSEPH | reporter.nih.gov |
| The Pacific Northwest Prostate Cancer SPORE | NIH | National Cancer Institute | 2021 to 2025 | $9,924,776 | September 19, 2002 | August 31, 2028 | NELSON, PETER S | reporter.nih.gov |
| Cancer Epidemiology Cohort in Male Health Professionals | NIH | National Cancer Institute | 2021 to 2025 | $7,706,351 | August 21, 2012 | July 31, 2027 | MUCCI, LORELEI | reporter.nih.gov |
| University of Arizona Cancer Prevention Clinical Trials Network | NIH | National Cancer Institute | 2021 to 2025 | $7,572,043 | August 16, 2019 | July 31, 2031 | THOMPSON, PATRICIA ANN | reporter.nih.gov |
| iCAN PREVENT: MD Anderson International Cancer Prevention Clinical Trials Consortium | NIH | National Cancer Institute | 2021 to 2025 | $7,046,172 | August 15, 2019 | July 31, 2031 | VILAR SANCHEZ, EDUARDO | reporter.nih.gov |
| Transcriptomic classification of non-muscle invasive bladder cancer and its clinical and prognostic implication | NIH | National Cancer Institute | 2022 to 2025 | $6,547,653 | September 1, 2025 | August 31, 2027 | TANG, LI | reporter.nih.gov |
| NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care | NIH | National Cancer Institute | 2021 to 2025 | $5,422,908 | March 5, 2019 | February 28, 2026 | BURSTEIN, HAROLD JOHN | reporter.nih.gov |
| Genomic and Genomic Variation in Prostate Cancer | NIH | National Cancer Institute | 2022 to 2025 | $5,164,514 | January 7, 2022 | April 30, 2027 | REBBECK, TIMOTHY RICHARD | reporter.nih.gov |
| Human Prostate Tumor Atlas Center | NIH | National Cancer Institute | 2024 to 2025 | $5,162,603 | September 1, 2024 | August 31, 2029 | DING, LI | reporter.nih.gov |
| The stromal microenvironment as a co-organizer of bladder carcinogenesis and progression | NIH | National Cancer Institute | 2023 to 2025 | $5,126,849 | September 22, 2022 | August 31, 2027 | CHAN, KEITH SYSON | reporter.nih.gov |
| Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium Scientific and Data Coordinating Center | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $5,116,812 | July 15, 2015 | June 30, 2026 | RUDSER, KYLE | reporter.nih.gov |
| Integrating targeted therapy and immunotherapy to break through cancer | NIH | National Cancer Institute | 2021 to 2025 | $5,025,838 | September 1, 2016 | August 31, 2030 | ZHAO, JEAN | reporter.nih.gov |
| Continuation of the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) Data Coordinating Center | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $4,791,062 | September 1, 2025 | August 31, 2026 | GRAFF, JOHN JOSEPH | reporter.nih.gov |
| Post genome wide association studies in testicular germ cell tumors | NIH | National Cancer Institute | 2021 to 2024 | $4,743,103 | September 21, 2012 | August 31, 2025 | NATHANSON, KATHERINE L. | reporter.nih.gov |
| New class of PBP inhibitors to address PBP2-mediated resistance in Neisseria gonorrhoeae | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,603,680 | September 5, 2019 | August 31, 2025 | DAIGLE, DENIS MARC | reporter.nih.gov |
| Modeling Precision Interventions for Prostate Cancer Control | NIH | National Cancer Institute | 2021 to 2025 | $4,423,369 | June 15, 2025 | August 31, 2026 | ETZIONI, RUTH D | reporter.nih.gov |
| Genetic Susceptibility and Biomarkers of Platinum-related Toxicities | NIH | National Cancer Institute | 2021 to 2025 | $4,370,186 | September 25, 2012 | June 30, 2027 | TRAVIS, LOIS B. | reporter.nih.gov |
| Regulation of Cell Fate during Kidney Development and Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $4,360,112 | September 21, 2012 | August 31, 2027 | GOMEZ, ROBERTO ARIEL | reporter.nih.gov |
| Urology Centers Program Interactions Core (U24) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $4,277,500 | September 17, 2020 | July 31, 2030 | PENNISTON, KRISTINA L | reporter.nih.gov |
| Supplement for Development and Translation of Specialized Hyperpolarized C-13 MRI Methods for Alzheimer's Disease | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $4,113,467 | June 1, 2019 | February 28, 2025 | VIGNERON, DANIEL B | reporter.nih.gov |
| Urinary Stone Disease Research Network: Scientific Data Research Center | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2024 | $4,080,466 | September 1, 2016 | November 30, 2025 | SCALES, CHARLES D | reporter.nih.gov |
| Bedside to bench resources for lower urinary tract research | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $4,039,744 | September 15, 2022 | May 31, 2027 | STRAND, DOUGLAS WILLIAM | reporter.nih.gov |
| Neisseria gonorrhoeae exploits host interferon epsilon to establish infection in the female urogenital tract | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,970,913 | July 1, 2021 | June 30, 2027 | GOLENBOCK, DOUGLAS T | reporter.nih.gov |
| PNPase inhibition as an effective treatment for chronic bladder pain | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $3,942,335 | September 24, 2022 | August 31, 2027 | BIRDER, LORI A | reporter.nih.gov |
| Efficacy of immunization with 4C-MenB in preventing experimental urethral infection with Neisseria gonorrhoeae. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,925,773 | July 1, 2021 | April 30, 2027 | DUNCAN, JOSEPH A | reporter.nih.gov |
| Digital Uroflowmetry for Office and Home | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,880,133 | September 18, 2023 | August 31, 2026 | FEDOROVSKY, ROMAN | reporter.nih.gov |
| HIV Persistence and Renewal in the Gastrointestinal, Genitourinary and Adipose Tissues | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,879,562 | September 17, 2021 | July 31, 2026 | SMITH, DAVID MITCHELL | reporter.nih.gov |
| Proof-of-Concept and Mechanistic Studies to Repurpose Erectile Dysfunction Drugs for Elderly Females | NIH | National Institute on Aging | 2021 to 2025 | $3,872,647 | May 1, 2021 | February 28, 2026 | YUEN, TONY | reporter.nih.gov |
| Modeling and analytics for cancer diagnostics: traversing the data-evidence divide | NIH | National Cancer Institute | 2022 to 2025 | $3,872,365 | September 1, 2022 | August 31, 2029 | ETZIONI, RUTH D | reporter.nih.gov |
| GEMS: Genomic approach to connecting Elevated germline Mutation rates with male infertility and Somatic health | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,803,952 | September 1, 2021 | May 31, 2027 | HOTALING, JAMES | reporter.nih.gov |
| Cognitive, urinary, and functional trajectories of older women using pharmacologic treatment strategies for urgency incontinence | NIH | National Institute on Aging | 2022 to 2025 | $3,733,157 | February 15, 2022 | January 31, 2027 | HUANG, ALISON | reporter.nih.gov |
| Structure-based functional annotation of microbial genomes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,660,701 | August 1, 2018 | July 31, 2027 | FREDDOLINO, LYDIA PETRA | reporter.nih.gov |
| Genetic Predictors of Prostate Cancer Survival | NIH | National Cancer Institute | 2021 to 2025 | $3,655,797 | January 15, 2021 | December 31, 2026 | KLEIN, ROBERT J. | reporter.nih.gov |
| Exploring Precision Oncology: From Gene Fusions to lncRNAs | NIH | National Cancer Institute | 2021 to 2024 | $3,631,025 | September 1, 2018 | August 31, 2025 | CHINNAIYAN, ARUL M | reporter.nih.gov |
| PSMA’s enzymatic activity as new target for Prostate Cancer diagnosis and therapy | NIH | National Cancer Institute | 2021 to 2025 | $3,606,632 | July 1, 2021 | June 30, 2027 | GRIMM, JAN | reporter.nih.gov |
| Mechanism of the Fluoroquinolone Resistance Acquisition in Enterobacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,553,622 | April 6, 2021 | September 30, 2026 | SOKURENKO, EVGENI VENIAMINOVIC | reporter.nih.gov |
| Biochemical and cellular mechanisms linking actin mutations to visceral myopathy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,487,348 | September 28, 2021 | August 31, 2027 | HEUCKEROTH, ROBERT O | reporter.nih.gov |
| National Institute of Diabetes and Digestive and Kidney Diseases ATLAS (D2K-ATLAS) Center as an accessible, comprehensive data portfolio for renal and genitourinary development and disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2023 | $3,444,502 | September 25, 2022 | July 31, 2027 | VALERIUS, MICHAEL TODD | reporter.nih.gov |
| Epidemiologic and molecular basis of the gut-urinary tract axis in urinary tract infection | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,416,719 | June 12, 2020 | July 31, 2030 | HULTGREN, SCOTT J. | reporter.nih.gov |
| Population Modeling of Bladder Cancer Detection and Control | NIH | National Cancer Institute | 2021 to 2025 | $3,415,778 | September 13, 2021 | August 31, 2026 | TRIKALINOS, THOMAS | reporter.nih.gov |
| Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,403,254 | February 9, 2021 | January 31, 2027 | GOLDKORN, AMIR | reporter.nih.gov |
| Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant Gonorrhea | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,356,811 | August 8, 2022 | July 31, 2026 | WANG, LAURENE | reporter.nih.gov |
| Elucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approaches | NIH | National Cancer Institute | 2021 to 2025 | $3,352,278 | March 2, 2021 | February 28, 2027 | FREEDMAN, MATTHEW L | reporter.nih.gov |
| Development of 21st Century Concepts and Tools for Quantifying Urethral Failure Mechanisms that Cause Urinary Incontinence | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $3,346,721 | September 18, 2019 | June 30, 2025 | DELANCEY, JOHN O.L. | reporter.nih.gov |
| Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studies | NIH | National Cancer Institute | 2022 to 2025 | $3,342,109 | September 1, 2022 | August 31, 2027 | FREEDMAN, MATTHEW L | reporter.nih.gov |
| MULTIPLEXED PROTEIN BIOMARKER-BASED ASSAY FOR THE DETECTION OF BLADDER CANCER | NIH | National Cancer Institute | 2021 to 2025 | $3,326,498 | May 1, 2016 | July 31, 2027 | ROSSER, CHARLES J | reporter.nih.gov |
| Career Development in Pediatric and Medical Oncology | NIH | National Cancer Institute | 2021 to 2025 | $3,314,336 | September 30, 1997 | August 31, 2026 | MESHINCHI, SOHEIL | reporter.nih.gov |
| Measuring Metabolic Activity in Prostate Cancer Bone Metastases Using Hyperpolarized 13C Pyruvate MRI for Improved Targeted Therapy Monitoring | NIH | National Cancer Institute | 2021 to 2025 | $3,288,067 | December 1, 2020 | November 30, 2026 | VIGNERON, DANIEL B | reporter.nih.gov |
| Hyperpolarized C-13 MRI Techniques to Monitor Radiation Therapy Response in Prostate Cancer Patients | NIH | National Cancer Institute | 2021 to 2025 | $3,266,535 | July 1, 2021 | June 30, 2027 | VIGNERON, DANIEL B | reporter.nih.gov |
| A BRIEF, TRANSDIAGNOSTIC COGNITIVE BEHAVIORAL TREATMENT FOR UROLOGIC CHRONIC PELVIC PAIN SYNDROME (UCPPS): PROCESS, PREDICTIONS, OUTCOMES | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,263,376 | September 21, 2021 | July 31, 2027 | LACKNER, JEFFREY M | reporter.nih.gov |
| Collagen-based tissue guidance biofabric for treatment of stress urinary incontinence in women | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,259,681 | April 15, 2020 | May 31, 2027 | SHANKAR, SUBBA | reporter.nih.gov |
| Prostate cancer Active Surveillance Study (PASS) Cohort: Infrastructure Support for Cancer Research | NIH | National Cancer Institute | 2021 to 2023 | $3,239,571 | September 20, 2019 | August 31, 2025 | LIN, DANIEL W. | reporter.nih.gov |
| Pathomic Predictors of Prostate Cancer Progression | NIH | National Cancer Institute | 2021 to 2024 | $3,202,938 | April 16, 2020 | March 31, 2026 | MALLICK, PARAG KUMAR | reporter.nih.gov |
| USDHub: community resource for Urinary Stone Disease research | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $3,202,605 | August 22, 2024 | May 31, 2026 | HSI, RYAN | reporter.nih.gov |
| Impact of ocular microbiome, immune response and Chlamydiae on trachoma following MDA | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,190,228 | July 1, 2022 | June 30, 2027 | DEAN, DEBORAH ANNE | reporter.nih.gov |
| Role of AJC in umbrella cell function and dysfunction | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,179,860 | September 6, 2021 | June 30, 2027 | APODACA, GERARD L | reporter.nih.gov |
| Natural History of C. trachomatis urogenital and rectal infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,179,786 | March 20, 2020 | February 28, 2026 | DEAN, DEBORAH ANNE | reporter.nih.gov |
| 3D High Resolution Magnetic Resonance Fingerprinting for Prostate Cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,177,909 | August 1, 2021 | July 31, 2027 | JIANG, YUN | reporter.nih.gov |
| Genomic profiling of single circulating tumor cells in the precision medicine of metastatic prostate cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,177,343 | July 8, 2021 | June 30, 2027 | YANG, HUSHAN | reporter.nih.gov |
| An integrated exercise and bladder training intervention to reduce falls in older women with urinary incontinence | NIH | National Institute on Aging | 2021 to 2025 | $3,172,146 | September 30, 2021 | August 31, 2026 | ANDY, UDUAK UMOH | reporter.nih.gov |
| Prostate Cancer Biomarker and Imaging Validation Alliance: Emory University, University of Alabama Birmingham, and University of Texas Southwestern | NIH | National Cancer Institute | 2021 to 2025 | $3,170,165 | March 29, 2005 | June 30, 2028 | SANDA, MARTIN G. | reporter.nih.gov |
| Next Generation Therapies for Fertility Preservation in Male Cancer Patients | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $3,165,939 | May 15, 2020 | April 30, 2025 | ORWIG, KYLE EDWIN | reporter.nih.gov |
| Enabling clinical tissue microstructure imaging as a diagnostic tool in wide-bore 3T MRI | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 to 2025 | $3,146,296 | September 1, 2023 | August 31, 2028 | FOO, THOMAS K | reporter.nih.gov |
| Coordinated studies in monkeys and humans to assess the immunological impact of rectal Chlamydia trachomatis infection on protection against genital infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,139,154 | April 1, 2023 | March 31, 2028 | VOJTECH, LUCIA N | reporter.nih.gov |
| Transrectal Histotripsy for Focal Ablation of Prostate Cancer | NIH | National Cancer Institute | 2022 to 2025 | $3,132,373 | September 23, 2022 | August 31, 2027 | SCHADE, GEORGE R | reporter.nih.gov |
| Noninvasive bladder cancer diagnostics via machine learning analysis of nanoscale surface images of epithelial cells extracted from voided urine samples | NIH | National Cancer Institute | 2021 to 2025 | $3,120,020 | August 1, 2021 | July 31, 2027 | SOKOLOV, IGOR | reporter.nih.gov |
| CNS Mechanisms of IC/BPS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,109,471 | August 1, 2018 | March 31, 2027 | GEREAU, ROBERT W | reporter.nih.gov |
| Targeting Interindividual Variability in NSAID Responses to Mitigate Chronic Pelvic Pain Risk in Dysmenorrhea | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 | $3,077,376 | September 17, 2024 | August 31, 2027 | HELLMAN, KEVIN | reporter.nih.gov |
| Cumulative burden of Chlamydia trachomatis and Mycoplasma genitalium in the US: implications for screening guidelines and antimicrobial resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,074,527 | May 1, 2021 | April 30, 2027 | MANHART, LISA E | reporter.nih.gov |
| A transdisciplinary approach for dissecting stem cell states in prostate cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,070,312 | September 20, 2021 | August 31, 2026 | RABADAN, RAUL | reporter.nih.gov |
| Multiethnic GWAS and TWAS to Inform Risk Prediction for Prostate Cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,068,628 | May 1, 2025 | April 30, 2027 | HAIMAN, CHRISTOPHER ALAN | reporter.nih.gov |
| Development of novel anti-Neisseria gonorrhoeae therapeutic agents | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,055,792 | August 12, 2022 | July 31, 2027 | FLAHERTY, DANIEL PATRICK | reporter.nih.gov |
| Identifying Opportunities for Prevention of Adverse Outcomes Following Female Genital Fistula Repair | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,054,428 | May 1, 2021 | February 28, 2027 | EL AYADI, ALISON M | reporter.nih.gov |
| Patient-Derived Models of Prostate Cancer for Personalized Medicine | NIH | National Cancer Institute | 2021 to 2023 | $3,037,013 | August 1, 2019 | July 31, 2025 | FUTREAL, PHILLIP ANDREW | reporter.nih.gov |
| Identifying factors associated with prostate cancer progression and survival in African American men: The RESPOND Cohort | NIH | National Cancer Institute | 2024 to 2025 | $3,024,739 | July 23, 2024 | June 30, 2029 | HAIMAN, CHRISTOPHER ALAN | reporter.nih.gov |
| New York Consortium for Interdisciplinary Training in Kidney, Urological and Hematological Research (NYC Train KUHR) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $3,023,587 | September 15, 2022 | June 30, 2027 | KASKEL, FREDERICK JEFFREY | reporter.nih.gov |
| Prognostic and Predictive Digital Tissue Image Assay for Prostate Cancer | NIH | National Cancer Institute | 2022 to 2025 | $3,008,190 | September 5, 2022 | August 31, 2027 | MADABHUSHI, ANANT | reporter.nih.gov |
| MECHANISMS OF AGE-and SEX- DEPENDENT CHANGES IN URINARY BLADDER IMMUNITY | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $3,005,541 | September 15, 2025 | August 31, 2029 | MYSOREKAR, INDIRA U | reporter.nih.gov |
| Eco-evolutionary dynamics of Escherichia coli in an island system: Environmental drivers of waterborne urinary tract infections | NIH | Fogarty International Center | 2025 | $3,000,004 | September 9, 2025 | August 31, 2030 | STEWART, JILL RENE | reporter.nih.gov |
| Preclinical and Early Clinical Development of a Novel Drug for On-Demand Voiding | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $2,992,699 | March 1, 2023 | February 28, 2027 | BURGARD, EDWARD | reporter.nih.gov |
| Signal integration by specialized mesenchyme in urothelial homeostasis and Interstitial Cystitis / Bladder Pain Syndrome | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,991,425 | September 24, 2022 | August 31, 2027 | BEACHY, PHILIP A | reporter.nih.gov |
| Computer Aided Diagnostic System for Prostate Cancer Detection Using Quantitative Multiparametric MRI | NIH | National Cancer Institute | 2021 to 2025 | $2,990,455 | September 23, 2021 | August 31, 2027 | METZGER, GREGORY JOHN | reporter.nih.gov |
| Rapid antimicrobial susceptibility testing directly from urine specimens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,974,719 | April 1, 2021 | March 31, 2024 | BURG, LAWRENCE | reporter.nih.gov |
| Somatic Truncation Mutations of the Histone Methyltransferase MLL4 Alter Its Subcellular Localization in Bladder Cancer: Mechanistic Insight and Targeted Therapeutic Approach | NIH | National Cancer Institute | 2025 | $2,970,010 | September 16, 2025 | August 31, 2029 | SHILATIFARD, ALI | reporter.nih.gov |
| Defining the role of histone H3K4 mono-methyltransferase dysfunction in urothelial carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $2,969,354 | September 1, 2025 | August 31, 2027 | CHEN, YU | reporter.nih.gov |
| Molecular Clonality of Uropathogenic E. Coli | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,968,549 | November 19, 2013 | April 30, 2026 | SOKURENKO, EVGENI VENIAMINOVIC | reporter.nih.gov |
| Prostate Cancer Radio-Pathomics for Differentiating Clinically Significant Disease | NIH | National Cancer Institute | 2021 to 2025 | $2,965,890 | March 1, 2021 | August 31, 2026 | LAVIOLETTE, PETER S | reporter.nih.gov |
| Cystoscopy-augmenting tools to improve the sensitivity and specificity of detection of urothelial carcinoma in situ | NIH | National Cancer Institute | 2025 | $2,958,465 | September 19, 2025 | August 31, 2029 | BOWDEN, AUDREY KYNSELLA | reporter.nih.gov |
| Blood-based monitoring of bladder-sparing trimodality therapy for muscle-invasive bladder cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,958,001 | September 1, 2022 | August 31, 2027 | MIYAMOTO, DAVID T. | reporter.nih.gov |
| Rapid AST through Metabolic Imaging at Single Cell Level | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,949,272 | December 1, 2018 | June 30, 2027 | CHENG, JI-XIN | reporter.nih.gov |
| Molecular mechanisms underlying lineage plasticity in prostate cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,937,823 | April 1, 2025 | March 31, 2027 | BELTRAN, HIMISHA | reporter.nih.gov |
| The ESPINA Study 19th Year Follow-Up: A Longitudinal Investigation of Pesticide Exposures in relation to Fertility and Hormonal Health | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $2,937,308 | September 23, 2025 | June 30, 2030 | SUAREZ, JOSE RICARDO | reporter.nih.gov |
| An automated, scalable, and rapid AST system for Gonorrhea STIs | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,934,394 | January 15, 2021 | December 31, 2023 | SWIGER, ROY R | reporter.nih.gov |
| Early clinial trials for Angelica herbal supplements for prostate cancer interception | NIH | National Cancer Institute | 2022 to 2025 | $2,932,860 | September 1, 2022 | August 31, 2027 | LU, JUNXUAN | reporter.nih.gov |
| Preventing invasive prostate cancer | NIH | National Cancer Institute | 2023 to 2025 | $2,928,553 | September 19, 2023 | August 31, 2028 | BERGAN, RAYMOND C. | reporter.nih.gov |
| OpenIGTLink: a network communication interface for closed-loop image-guided interventions | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $2,909,122 | July 1, 2015 | January 31, 2026 | TOKUDA, JUNICHI | reporter.nih.gov |
| A Registry-Based Study of Patterns of Use of Targeted Therapies for Metastatic Cancers in Diverse Populations | NIH | National Cancer Institute | 2021 to 2025 | $2,899,424 | May 1, 2021 | November 30, 2025 | VEENSTRA, CHRISTINE | reporter.nih.gov |
| Understanding and targeting epigentic regulation of immune evasion in prostate cancer | NIH | National Cancer Institute | 2025 | $2,895,540 | August 1, 2025 | July 31, 2029 | CAI, LING | reporter.nih.gov |
| Zoonotic Uropathogenic Escherichia coli in Northwest Ecuador: Incidence and Risk Factors | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,885,415 | July 1, 2025 | June 30, 2027 | EISENBERG, JOSEPH N. S. | reporter.nih.gov |
| E. coli virulence gene expression during clinical UTIs in women | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,883,919 | July 1, 2022 | June 30, 2027 | ANDERSON, MARK T. | reporter.nih.gov |
| A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,858,436 | July 21, 2023 | June 30, 2027 | SEBAHAR, PAUL | reporter.nih.gov |
| Innovations in Shock Wave Lithotripsy Technology | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,856,681 | September 10, 1997 | March 31, 2027 | ZHONG, PEI | reporter.nih.gov |
| Targeting apoptotic cells to enhance radiotherapy | NIH | National Cancer Institute | 2022 to 2025 | $2,817,814 | September 22, 2022 | August 31, 2027 | RAO, JIANGHONG | reporter.nih.gov |
| Metabolomic Signatures of Urologic Chronic Pelvic Pain Syndrome | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,812,460 | July 15, 2021 | April 30, 2027 | HENDERSON, JEFFREY P | reporter.nih.gov |
| NIMBLE: Non-Invasive Markers of Bladder Deterioration | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,811,323 | September 6, 2021 | June 30, 2027 | LEE, RICHARD SANG-YONG | reporter.nih.gov |
| Allosteric adhesins of enterobacterial pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,798,011 | May 24, 2022 | April 30, 2027 | SOKURENKO, EVGENI VENIAMINOVIC | reporter.nih.gov |
| Biomarker Approaches to Individualizing Systemic Therapy for High Risk Prostate Cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,771,966 | July 1, 2020 | June 30, 2025 | FENG, FELIX YI-CHUNG | reporter.nih.gov |
| Uncovering causal protein markers to improve prostate cancer etiology understanding and risk prediction in Africans and Europeans | NIH | National Cancer Institute | 2022 to 2025 | $2,762,045 | July 1, 2022 | June 30, 2027 | WU, LANG | reporter.nih.gov |
| Mechanisms and Impact of Pregnancy-Induced Adaptations in Pelvic Floor Muscles | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $2,761,892 | August 1, 2017 | June 30, 2026 | ALPERIN, MARIANNA | reporter.nih.gov |
| Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI | NIH | National Cancer Institute | 2021 to 2024 | $2,760,490 | September 7, 2020 | August 31, 2025 | KURHANEWICZ, JOHN | reporter.nih.gov |
| Identifying Optimal Antibiotic Regimens to Treat Urinary Tract Infections During Pregnancy | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $2,760,230 | August 1, 2022 | April 30, 2027 | BUTLER, ANNE MOBLEY | reporter.nih.gov |
| High throughput infrastructure for reaction screening and bioassays | NIH | National Center for Advancing Translational Sciences | 2024 to 2025 | $2,752,647 | June 29, 2022 | May 31, 2027 | COOKS, ROBERT GRAHAM | reporter.nih.gov |
| Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,750,290 | April 1, 2020 | March 31, 2025 | BHARDWAJ, NINA | reporter.nih.gov |
| Investigating the mechanisms of driver genes associated with ancestry and aggressiveness in prostate cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,739,005 | May 10, 2021 | April 30, 2027 | CAMPBELL, JOSHUA D | reporter.nih.gov |
| Minimizing salivary gland and renal toxicity arising from PSMA-targeted alpha therapy | NIH | National Cancer Institute | 2022 to 2025 | $2,733,165 | May 1, 2022 | April 30, 2027 | PILLARSETTY, NAGAVARAKISHORE | reporter.nih.gov |
| Systemic RNA Delivery to Tumors | NIH | National Cancer Institute | 2021 to 2025 | $2,731,905 | December 21, 2015 | June 30, 2027 | SHI, JINJUN | reporter.nih.gov |
| Targeting DXP synthase in bacterial metabolism | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,729,986 | March 15, 2021 | February 28, 2027 | FREEL MEYERS, CAREN L. | reporter.nih.gov |
| DNA repair gene mutations and prostate cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,728,204 | December 2, 2019 | November 30, 2025 | SHEN, BINGHUI | reporter.nih.gov |
| Novel evidence-accumulation-driven methods for characterizing kidney stone progression | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,722,512 | March 1, 2022 | December 31, 2027 | LIU, YU-LUN | reporter.nih.gov |
| Cellular and molecular mediators of fibrosis in the development of urinary tract dysfunction | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $2,712,096 | September 24, 2014 | July 31, 2025 | RICKE, WILLIAM A | reporter.nih.gov |
| Deep South KUH Premier Research - Interdisciplinary Mentored Education (PRIME) Training Core | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,708,913 | September 1, 2023 | June 30, 2028 | POLLOCK, DAVID M | reporter.nih.gov |
| Metagenomic profiling of urinary cell-free DNA to monitor urinary tract infection after kidney transplantation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,705,917 | March 10, 2020 | February 28, 2026 | DE VLAMINCK, IWIJN | reporter.nih.gov |
| Efficacy of sipIT Intervention for Increasing Urine Output in Patients with Urolithiasis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,705,515 | September 15, 2020 | July 31, 2025 | CONROY, DAVID E. | reporter.nih.gov |
| Metastasis of PTEN Mutant Prostate Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,701,454 | September 1, 2022 | August 31, 2027 | TROTMAN, LLOYD C | reporter.nih.gov |
| LRRC8 anion channels, superoxide and RhoA in diabetic erectile dysfunction | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,699,596 | May 1, 2022 | April 30, 2027 | WEBB, R CLINTON | reporter.nih.gov |
| Understanding how T cell intrinsic androgen receptor activity influences cell differentiation and dysfunction | NIH | National Cancer Institute | 2021 to 2025 | $2,692,281 | July 6, 2021 | June 30, 2026 | MORAN, AMY E | reporter.nih.gov |
| Plk1 as a prognostic biomarker for prostate cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,686,273 | July 1, 2021 | June 30, 2026 | LIU, XIAOQI | reporter.nih.gov |
| Development of large-field-of-view hyperpolarized MRI | NIH | National Cancer Institute | 2021 to 2024 | $2,676,537 | December 1, 2019 | November 30, 2024 | KESHARI, KAYVAN R | reporter.nih.gov |
| Viral and host predictors of BK polyomavirus associated hemorrhagic cystitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,671,817 | July 1, 2020 | June 30, 2026 | LASKIN, BENJAMIN LEWIS | reporter.nih.gov |
| Physician Assistance Technology in Image-guided Robotic Intervention of Prostate | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $2,661,260 | August 1, 2021 | April 30, 2026 | HATA, NOBUHIKO | reporter.nih.gov |
| Clinical Qualification of Imaging and Fluid-Based Tumor Monitoring Biomarkers for Metastatic Castration Resistant Prostate Cancer | NIH | National Cancer Institute | 2023 to 2025 | $2,654,692 | July 1, 2020 | June 30, 2026 | SCHWARTZ, LAWRENCE H | reporter.nih.gov |
| Intravesical Immunotherapy of Spontaneous Canine Invasive Urothelial Carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $2,649,907 | September 1, 2022 | August 31, 2027 | ZAHAROFF, DAVID | reporter.nih.gov |
| Disrupting the Prostate Tumor Microenvironment in African American Men to Promote Response to Immuno-Modulatory Therapy | NIH | National Cancer Institute | 2022 to 2025 | $2,642,372 | September 1, 2022 | August 31, 2027 | YAMOAH, KOSJ | reporter.nih.gov |
| Effective combination therapy for MTAP-deficient bladder carcinoma by targeting metabolic vulnerability and modulating tumor immune microenvironment | NIH | National Cancer Institute | 2021 to 2025 | $2,641,385 | August 1, 2021 | July 31, 2027 | GAO, JIANJUN | reporter.nih.gov |
| Targeting the cGAS/STING Pathway to Overcome Resistance to Immune Checkpoint Inhibitors in PTEN-deficient Prostate Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,630,502 | September 20, 2022 | August 31, 2027 | PATNAIK, AKASH | reporter.nih.gov |
| Psychosocial Stress Effects on Regenerative Medicine Therapies for Lower Urinary Tract Disorders in Nonhuman Primates | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,630,241 | April 1, 2020 | March 31, 2026 | SHIVELY, CAROL A. | reporter.nih.gov |
| Nerve-Specific Fluorophores for Improved Nerve Sparing during Prostatectomy using the Clinical Fluorescence Guided Surgery Infrastructure | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $2,627,891 | August 5, 2021 | April 30, 2026 | GIBBS, SUMMER LYNNE | reporter.nih.gov |
| PSMA-targeted AuNPs for MR guided radiotherapy and radiosensitization | NIH | National Cancer Institute | 2021 to 2024 | $2,622,473 | March 1, 2021 | February 28, 2026 | BASILION, JAMES PETER | reporter.nih.gov |
| Development of the Next Generation of FABP5 Inhibitors to Treat Prostate Cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,618,639 | February 1, 2020 | January 31, 2026 | OJIMA, IWAO | reporter.nih.gov |
| Identification of key players mediating internalization of Trichomonas vaginalis extracellular vesicles by host cells and parasite adherence and survival in vivo | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,608,762 | June 2, 2020 | May 31, 2026 | JOHNSON, PATRICIA JEAN | reporter.nih.gov |
| Duke KURe Program | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,603,495 | August 1, 2013 | July 31, 2028 | AMUNDSEN, CINDY | reporter.nih.gov |
| UROLOGIC DISEASES IN AMERICA (UDA) COMPENDIUM | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2023 | $2,602,398 | September 29, 2023 | September 28, 2024 | BUIKA, KYLE | reporter.nih.gov |
| Insulin Signaling Activates Urothelial Defenses to Reduce Urinary Tract Infection Susceptibility | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,594,836 | September 24, 2021 | July 31, 2027 | SPENCER, JOHN DAVID | reporter.nih.gov |
| Impact of Body Composition and Related Inflammatory and Immune States on Prognosis of Non-Muscle Invasive Bladder Cancer | NIH | National Cancer Institute | 2023 to 2025 | $2,593,082 | June 14, 2023 | May 31, 2028 | KWAN, MARILYN L | reporter.nih.gov |
| Enhancing the Efficacy of Docetaxel in Prostate Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,590,555 | July 13, 2022 | June 30, 2027 | BALK, STEVEN P. | reporter.nih.gov |
| Identifying Cancer Recurrence with Novel Data Linkages with a Cancer Registry | NIH | National Cancer Institute | 2022 to 2025 | $2,585,593 | August 1, 2022 | July 31, 2027 | DOHERTY, JENNIFER ANNE | reporter.nih.gov |
| Molecular Determinants of Social Factors in Prostate Cancer | NIH | National Institute on Minority Health and Health Disparities | 2021 | $2,560,268 | September 26, 2017 | July 31, 2023 | KUMAR, DEEPAK | reporter.nih.gov |
| Molecular Biomarkers of Long-Term Response to Androgen Deprivation Therapy and Radiation in Prostate Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,551,647 | January 1, 2022 | December 31, 2026 | MAHER, CHRISTOPHER A | reporter.nih.gov |
| Novel Technologies to Isolate and Analyze Extrachromosomal DNAs for Diagnostic Applications | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $2,544,007 | August 1, 2023 | July 31, 2027 | SHOURA, MASSA | reporter.nih.gov |
| UroEDIC Bladder: Bladder Dysfunction in Type 1 Diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,536,849 | June 1, 2021 | March 31, 2026 | SARMA, ARUNA V | reporter.nih.gov |
| Prevention of pelvic floor muscle dysfunction with extracellular matrix hydrogel | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $2,535,698 | September 30, 2020 | June 30, 2026 | ALPERIN, MARIANNA | reporter.nih.gov |
| Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC | NIH | National Cancer Institute | 2022 to 2025 | $2,528,918 | September 16, 2020 | December 31, 2026 | HALABI, SUSAN | reporter.nih.gov |
| CARDIA-PLUS: A Life Course Investigation of Biopsychosocial Pathways to Bladder Health and Lower Urinary Tract Symptoms | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,525,060 | August 15, 2021 | July 31, 2025 | BRADY, SONYA S | reporter.nih.gov |
| Trial to Reduce Antimicrobial Use in Nursing home residents with Alzheimer's disease and other Dementias (TRAIN-AD) | NIH | National Institute on Aging | 2021 to 2025 | $2,515,460 | September 1, 2009 | December 31, 2027 | MITCHELL, SUSAN L | reporter.nih.gov |
| Methods to Test the Role of Age-related Lifestyle and Vaginal Microenvironment Changes and the Prevention, Treatment, and Progression of Genitourinary Syndrome of Menopause | NIH | National Institute on Aging | 2021 to 2025 | $2,513,445 | September 1, 2021 | May 31, 2027 | SHARDELL, MICHELLE DENISE | reporter.nih.gov |
| Bladder, Urethra and Anal Sphincter Reinnervation | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,512,195 | May 1, 2010 | June 30, 2025 | BARBE, MARY F | reporter.nih.gov |
| High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients | NIH | National Cancer Institute | 2022 to 2025 | $2,508,029 | December 17, 2021 | November 30, 2026 | PEPPONE, LUKE JOSEPH | reporter.nih.gov |
| Harnessing Antibody Responses to Prevent and Treat Urinary Tract Infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,502,664 | November 10, 2021 | October 31, 2026 | KAU, ANDREW LEON | reporter.nih.gov |
| Highly selective targeted theranostics for prostate cancers | NIH | National Cancer Institute | 2021 to 2024 | $2,486,011 | August 11, 2021 | July 31, 2026 | BASILION, JAMES PETER | reporter.nih.gov |
| ZC3H4 Driven Prostate Tissue Remodeling Triggered by Maladaptive Metabolic and Signaling Pathways | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $2,482,346 | September 15, 2025 | August 31, 2029 | PASCAL, LAURA ELLEN | reporter.nih.gov |
| Enhancing Epigenetic Analysis Of Rare Cells With Multi-Phase Microfluidics | NIH | National Cancer Institute | 2021 to 2024 | $2,478,422 | February 3, 2020 | January 31, 2026 | BEEBE, DAVID J | reporter.nih.gov |
| Oxalate formation from ascorbic acid | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,467,647 | April 1, 2021 | February 28, 2026 | KNIGHT, JOHN | reporter.nih.gov |
| Investigation of brain mechanisms involved in the Urinary Continence mechanism associated with aging | NIH | National Institute on Aging | 2021 to 2025 | $2,463,569 | September 1, 2020 | February 28, 2026 | CLARKSON, BECKY D | reporter.nih.gov |
| Preclinical analyses of advanced prostate cancer in genetically-engineered mice | NIH | National Cancer Institute | 2021 to 2025 | $2,462,511 | August 6, 2013 | January 31, 2028 | ABATE-SHEN, CORY | reporter.nih.gov |
| Multifunctional Regulation of Prostate Cancer Metabolism by Sigma1 Modulators | NIH | National Cancer Institute | 2021 to 2024 | $2,461,554 | January 13, 2020 | December 31, 2025 | KIM, FELIX JINHYUN | reporter.nih.gov |
| Genital Immune, Mucosal, and Viral Effects of Female Genital Schistosomiasis in Tanzania | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,453,764 | March 25, 2022 | February 28, 2027 | DOWNS, JENNIFER ALZOS | reporter.nih.gov |
| Multichannel Fluorescence Guided Surgery Tools Enabling Simultaneous Cancer Margin and Nerve Visualization in Prostatectomy | NIH | National Cancer Institute | 2022 to 2025 | $2,453,547 | May 10, 2022 | April 30, 2027 | GIBBS, SUMMER LYNNE | reporter.nih.gov |
| Repurposing rifampin to reduce elevated levels of blood and urine calcium in patients with inactivating mutations of CYP24A1 | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,442,150 | December 23, 2022 | November 30, 2027 | LEVINE, MICHAEL A. | reporter.nih.gov |
| Elucidation of the mechanisms by which cells recognize and respond to different levels of androgens | NIH | National Cancer Institute | 2022 to 2025 | $2,436,399 | September 1, 2022 | July 31, 2027 | MCDONNELL, DONALD P | reporter.nih.gov |
| Ionization Detail - Biologically based treatment planning for particle therapy beyond LET-RBE | NIH | National Cancer Institute | 2022 to 2025 | $2,434,477 | September 1, 2022 | August 31, 2027 | FADDEGON, BRUCE | reporter.nih.gov |
| Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification | NIH | National Cancer Institute | 2021 to 2024 | $2,427,569 | March 1, 2020 | February 28, 2026 | SUNG, KYUNG HYUN | reporter.nih.gov |
| Enhancing the efficacy of androgen signaling inhibitors in prostate cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,422,948 | July 1, 2021 | June 30, 2026 | LIU, XIAOQI | reporter.nih.gov |
| High resolution transcriptome and gene regulatory mapping of human ureter and bladder across the lifespan | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,415,000 | September 30, 2021 | July 31, 2027 | WESSELY, OLIVER | reporter.nih.gov |
| Precision Prostate Cancer Screening with Genetically Adjusted Prostate-Specific Antigen Levels | NIH | National Cancer Institute | 2021 to 2025 | $2,414,500 | April 1, 2020 | March 31, 2030 | WITTE, JOHN S. | reporter.nih.gov |
| Pelvic fascia spARing radical prostatectomy TrIAL (PARTIAL) | NIH | National Cancer Institute | 2022 to 2025 | $2,411,833 | February 4, 2022 | July 31, 2028 | HU, JIM | reporter.nih.gov |
| PSMA-PET to Guide Prostatectomy: Can PSMA-PET Appropriately Modify Surgery, Reduce Nerve Damage and Optimize Quality-of-Life? | NIH | National Cancer Institute | 2022 to 2025 | $2,408,587 | March 1, 2022 | February 28, 2027 | BAHLER, CLINTON DAVID | reporter.nih.gov |
| Microfluidic isolation and molecular analysis of circulating tumor cells for the study of neuroendocrine transdifferentiation in prostate cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,406,187 | April 1, 2022 | March 31, 2027 | TONER, MEHMET | reporter.nih.gov |
| Targeting Castration Resistant Prostate Cancer via Potent Inhibition of Signaling Lipids | NIH | National Cancer Institute | 2022 to 2025 | $2,404,562 | September 1, 2022 | August 31, 2027 | KAOCHAR, SALMA | reporter.nih.gov |
| ZW800-1: The 1st Zwitterionic NIR Fluorophore for Cancer Imaging & Ureter Mapping | NIH | National Cancer Institute | 2021 to 2022 | $2,403,716 | December 8, 2016 | May 31, 2023 | FRANGIONI, JOHN V | reporter.nih.gov |
| Development of an Innovative PSMA-Targeted Small Molecule Prodrug for Prostate Cancer | NIH | National Cancer Institute | 2024 to 2025 | $2,399,998 | September 2, 2024 | August 31, 2026 | LANGTON-WEBSTER, BEATRICE | reporter.nih.gov |
| Development of Enabling Technologies for Clinical Ultrahigh Field Body MRI | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $2,392,254 | April 15, 2021 | December 31, 2025 | METZGER, GREGORY JOHN | reporter.nih.gov |
| How sex, host microenvironment, and immune responses shape acquisition of genital bacteria that increase HIV risk | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,387,782 | December 1, 2021 | November 30, 2026 | LIU, CINDY | reporter.nih.gov |
| Evaluation of Transperineal Biopsy under Local Anesthesia, a Novel approach to Decrease Post-Biopsy Infections and Improve Cancer Detection | NIH | National Cancer Institute | 2021 to 2024 | $2,384,687 | September 11, 2020 | June 30, 2025 | HU, JIM | reporter.nih.gov |
| Noninvasive assessment of detrusor pressure and dysfunction | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,382,351 | February 15, 2022 | December 31, 2026 | FATEMI, MOSTAFA | reporter.nih.gov |
| Ultra-Low Count Quantitative SPECT for Alpha-Particle Therapies | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $2,381,642 | September 30, 2022 | June 30, 2027 | JHA, ABHINAV K | reporter.nih.gov |
| Functional Characterization and Development of Therapeutic Paradigms for DNA Damage Repair (DDR)-deficient Lethal Prostate Cancer | NIH | National Cancer Institute | 2023 to 2025 | $2,380,224 | April 1, 2023 | March 31, 2028 | CHAKRABORTY, GOUTAM | reporter.nih.gov |
| Molecular imaging of novel PARP inhibitor nanomedicine delivery | NIH | National Cancer Institute | 2022 to 2025 | $2,377,967 | August 12, 2022 | July 31, 2027 | VANBROCKLIN, HENRY F. | reporter.nih.gov |
| High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,374,172 | August 6, 2021 | July 31, 2025 | CASTRO, CESAR M | reporter.nih.gov |
| Real-world effectiveness of preventive pharmacological therapy for patients with kidney stones | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,372,377 | April 1, 2020 | March 31, 2026 | SHAHINIAN, VAHAKN B | reporter.nih.gov |
| Chemotherapy and the Bladder Cancer Immune Microenvironment | NIH | National Cancer Institute | 2021 to 2024 | $2,371,427 | August 1, 2020 | April 30, 2025 | KIM, WILLIAM Y. | reporter.nih.gov |
| MELT: Modulation of PSMA Expression for Lutetium Therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,363,818 | July 1, 2019 | June 30, 2026 | HOPE, THOMAS A | reporter.nih.gov |
| Pathogenic Fiber Formation in Bacteria: Structural Basis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,362,500 | February 1, 2001 | March 31, 2026 | HULTGREN, SCOTT J. | reporter.nih.gov |
| Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,358,284 | July 1, 2020 | June 30, 2026 | DIEHN, MAXIMILIAN | reporter.nih.gov |
| NOT-CA-24-111 Improving Strategies for Cancer Reduction through Early-detection and ENgagement (I-SCREEN) | NIH | National Cancer Institute | 2024 to 2025 | $2,357,813 | February 14, 2024 | December 31, 2027 | COOK, LINDA S | reporter.nih.gov |
| Kidney Stone Disease In ADPKD | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,353,533 | September 22, 2021 | June 30, 2027 | CHONCHOL, MICHEL BENJAMIN | reporter.nih.gov |
| Bioengineered Prostate-on Chip: Mechanisms of Stromal Dysregulation in Prostate Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,349,240 | April 7, 2021 | March 31, 2027 | MIRANTI, CYNTHIA K | reporter.nih.gov |
| traThe influence of rectal Chlamydia trachomatis infections on immunity and incident urogenital infections in women without an indication forrectal screening | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,340,405 | July 6, 2023 | June 30, 2028 | JORDAN, STEPHEN J. | reporter.nih.gov |
| Novel therapeutics dual targeting intracrine androgen synthesis and AR for advanced prostate cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,339,824 | April 1, 2022 | March 31, 2027 | GAO, ALLEN C. | reporter.nih.gov |
| PDE5 Inhibition of Afferents and Interstitial Cells in Overactive Mouse Bladders | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,336,406 | September 20, 2014 | June 30, 2026 | KANAI, ANTHONY JOHN | reporter.nih.gov |
| The natural history of C. trachomatis urethral infections in men who have sex with women | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,335,516 | July 5, 2023 | June 30, 2028 | NELSON, DAVID EMMET | reporter.nih.gov |
| Elucidating hallmarks of aging in the development of lower urinary tract dysfunction (LUTD) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,333,592 | September 24, 2021 | August 31, 2025 | RICKE, WILLIAM A | reporter.nih.gov |
| Essential roles for RNAi/hpRNAs to resolve intragenomic conflicts in the male germline | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $2,333,198 | May 3, 2022 | April 30, 2027 | LAI, ERIC C | reporter.nih.gov |
| Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,331,598 | April 1, 2021 | March 31, 2027 | REJNIAK, KATARZYNA ANNA | reporter.nih.gov |
| PCPT and SELECT Cohorts: Core Infrastructure Support for Cancer Research | NIH | National Cancer Institute | 2021 to 2023 | $2,327,659 | September 20, 2013 | July 31, 2025 | TANGEN, CATHERINE M. | reporter.nih.gov |
| Real time fine needle assessment of architectural heterogeneity in prostate cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,327,219 | January 18, 2019 | December 31, 2025 | XU, GUAN | reporter.nih.gov |
| Molecular mechanisms of prostate cancer metastasis | NIH | National Cancer Institute | 2021 to 2025 | $2,326,612 | January 1, 2015 | June 30, 2027 | ABATE-SHEN, CORY | reporter.nih.gov |
| Measuring and Predicting Appropriate Antibiotic Use to Combat Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,321,762 | July 1, 2023 | June 30, 2028 | CHEN, JONATHAN H. | reporter.nih.gov |
| Noninvasive, Uniplex, Molecular, Pathomic Urinary Assay for Detection of Prostate Cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,321,414 | September 1, 2020 | May 31, 2026 | THAKUR, MATHEW LAXMAN | reporter.nih.gov |
| Sexual Dimorphism in Bladder Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,318,010 | August 2, 2022 | July 31, 2027 | LI, XUE SEAN | reporter.nih.gov |
| Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependence | NIH | National Cancer Institute | 2021 to 2025 | $2,315,488 | April 1, 2015 | August 31, 2025 | SAWYERS, CHARLES L. | reporter.nih.gov |
| Interplay between tumor and microenvironment in bone metastasis | NIH | National Cancer Institute | 2021 to 2025 | $2,312,393 | April 1, 2021 | March 31, 2026 | FISHER, PAUL B | reporter.nih.gov |
| Increasing nerve-sparing radical prostatectomy rates using intraoperative nonlinear microscopy | NIH | National Cancer Institute | 2021 to 2025 | $2,308,361 | February 5, 2021 | January 31, 2027 | FUJIMOTO, JAMES G | reporter.nih.gov |
| Using Prostate Health Index and MRI in Combination for Cost-effectively Detecting High-Grade Prostate Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,307,356 | September 14, 2020 | June 30, 2026 | MURPHY, ADAM B | reporter.nih.gov |
| Super Resolution for Improved Multislice Prostate MRI | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $2,303,815 | July 10, 2022 | May 31, 2026 | RIEDERER, STEPHEN J | reporter.nih.gov |
| How E. coli Acid Response Mechanisms Breach Colonization Resistance in the Vagina | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,302,945 | July 1, 2022 | June 30, 2027 | HADJIFRANGISKOU, MARIA | reporter.nih.gov |
| Rad-pathomic deep learning models to assist radiologists in differentiating aggressive from indolent prostate cancer on MRI | NIH | National Cancer Institute | 2022 to 2025 | $2,302,630 | January 12, 2022 | December 31, 2026 | RUSU, MIRABELA | reporter.nih.gov |
| Creating high-resolution multi-omics molecular atlases for developing urogenital organs | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,298,845 | September 30, 2021 | July 31, 2027 | CHEN, FENG | reporter.nih.gov |
| Prostate Cancer Diagnosis by Multiparametric Ultrasound | NIH | National Cancer Institute | 2021 to 2024 | $2,294,658 | July 1, 2020 | June 30, 2025 | FORSBERG, FLEMMING | reporter.nih.gov |
| Impact of Amygdala Lateralization on Processing and Modulation of Bladder Pain | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,294,587 | August 1, 2018 | August 31, 2028 | KOLBER, BENEDICT J | reporter.nih.gov |
| HFH-MSU CSRN ACCrual Enrollment and Screening Site | NIH | National Cancer Institute | 2024 to 2025 | $2,289,116 | March 7, 2025 | December 31, 2027 | NESLUND-DUDAS, CHRISTINE MARIE | reporter.nih.gov |
| Molecular mechanisms of initiation of benign prostatic hyperplasia | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,288,674 | July 1, 2016 | April 30, 2026 | XIN, LI | reporter.nih.gov |
| DeepSRH: Transforming Molecular Cancer Screening with Stimulated Raman Histology and Deep Neural Networks | NIH | National Cancer Institute | 2025 | $2,284,054 | September 1, 2025 | August 31, 2029 | HOLLON, TODD CHARLES | reporter.nih.gov |
| Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes- MERIT extension | NIH | National Cancer Institute | 2021 to 2024 | $2,282,522 | July 1, 2018 | May 31, 2026 | HAMILTON-REEVES, JILL REEVES | reporter.nih.gov |
| Neural Mechanisms Underlying IC/BPS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,281,071 | May 5, 2021 | February 28, 2027 | SAMINENI, VIJAY K | reporter.nih.gov |
| Mechanisms of microenvironment mediated resistance to cancer cell surface targeted therapeutics | NIH | National Cancer Institute | 2022 to 2024 | $2,279,178 | September 15, 2020 | August 31, 2025 | BEEBE, DAVID J | reporter.nih.gov |
| Contribution of immune modulation, metabolism, and microbiota to Group B Streptococcal urinary tract infection | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,277,552 | September 21, 2021 | June 30, 2027 | PATRAS, KATY | reporter.nih.gov |
| Bridges-Round 2: Evaluating the Long-term Impact of a Family Economic Empowerment Intervention on HIV Risk Prevention and Care Continuum Outcomes among Orphaned Youth Transitioning to Young Adulthood | NIH | National Institute of Mental Health | 2022 to 2025 | $2,274,945 | March 17, 2022 | February 28, 2027 | SSEWAMALA, FRED M | reporter.nih.gov |
| Intermittent Fasting using a Fasting-Mimetic Diet to Improve Prostate Cancer Control and Metabolic Outcomes | NIH | National Cancer Institute | 2023 to 2025 | $2,274,110 | July 1, 2023 | June 30, 2028 | FREEDLAND, STEPHEN JAY | reporter.nih.gov |
| Advancing immunotherapy through cross species studies of immune cell responses and immune checkpoint inhibitor effects in dogs and humans with invasive urinary bladder cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,273,957 | September 1, 2022 | August 31, 2027 | KNAPP, DEBORAH W | reporter.nih.gov |
| The single and same cell 3D atlas of epigenome and transcriptome of the lower urinary tract | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,268,728 | September 30, 2021 | July 31, 2027 | LI, XUE SEAN | reporter.nih.gov |
| Aligning financial incentives to promote rational use of active surveillance for prostate cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,252,166 | April 1, 2022 | March 31, 2027 | SHAHINIAN, VAHAKN B | reporter.nih.gov |
| STING agonist-expressing BCG for bladder cancer | NIH | National Cancer Institute | 2021 to 2023 | $2,244,436 | September 1, 2021 | July 31, 2025 | WALLACH, TODD | reporter.nih.gov |
| Digital Multiplexed Analysis of Circulating Nucleic Acids in Small-Volume Blood Specimens | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $2,239,028 | August 15, 2022 | May 31, 2026 | SMITH, ANDREW MICHAEL | reporter.nih.gov |
| Phase IIB Clinical and Nonclinical Testing of Soft Spring Continence Pessary for Women, in Support of FDA 510(k) Clearance Requirements | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $2,236,995 | April 9, 2021 | June 30, 2025 | ROBERTS, MELODY ANN | reporter.nih.gov |
| Rewired Signaling at the Nexus of Melanoma Metastasis and Resistance | NIH | National Cancer Institute | 2021 to 2022 | $2,234,009 | February 2, 2016 | January 31, 2023 | RONAI, ZEEV A. | reporter.nih.gov |
| Protein RNA Rearrangements in the Spliceosome | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $2,217,484 | August 1, 1999 | January 31, 2027 | QUERY, CHARLES C | reporter.nih.gov |
| Validation and Identification of Genetic Variants in Peyronie's and Dupuytren's Disease that Predispose to Fibrosis and Inflammation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,194,947 | February 1, 2022 | December 31, 2026 | PASTUSZAK, ALEXANDER WOJCIECH | reporter.nih.gov |
| Development of Novel Targeted Therapeutic Agents for Castration Resistant Prostate Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,194,673 | June 3, 2022 | May 31, 2027 | OYELERE, ADEGBOYEGA | reporter.nih.gov |
| Mechanistic-Based Treatment of Interstitial Cystitis/Bladder Pain Syndrome | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,193,826 | May 5, 2023 | February 29, 2028 | MCKERNAN, LINDSEY COLMAN | reporter.nih.gov |
| Pathways underlying recovery of injured urethral sphincter and a novel regenerative biomaterial intervention | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,191,647 | July 15, 2021 | April 30, 2026 | ALPERIN, MARIANNA | reporter.nih.gov |
| Hsp60 Regulation of Prostate Cancer Progression | NIH | National Cancer Institute | 2021 to 2025 | $2,185,351 | September 1, 2021 | August 31, 2027 | CHANDRA, DHYAN | reporter.nih.gov |
| Improving Pediatric SPECT Imaging: Enhanced Lesion Detection with Dose Reduction through Advanced Reconstruction and Motion Correction | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $2,185,280 | June 1, 2020 | February 28, 2025 | KING, MICHAEL A | reporter.nih.gov |
| Lipoteichoic acid mediated modulation of chronic pain | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,182,686 | August 1, 2016 | June 30, 2027 | THUMBIKAT, PRAVEEN | reporter.nih.gov |
| Structure, function, and application of novel antagonists of the intrinsically disordered androgen receptor amino-terminal domain as imaging agents and therapeutics | NIH | National Cancer Institute | 2021 to 2025 | $2,182,643 | July 13, 2021 | June 30, 2027 | SADAR, MARIANNE D | reporter.nih.gov |
| A novel vaccine against multidrug-resistant gonorrhea | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,179,764 | January 1, 2019 | December 31, 2024 | RAM, SANJAY | reporter.nih.gov |
| Targeting AR and AR-Variants in Castration-Resistant Prostate Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,175,178 | February 1, 2021 | January 31, 2027 | DAMODARAN, CHENDIL | reporter.nih.gov |
| Oxalate-Driven Host Responses in Kidney Stone Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,172,481 | September 1, 2022 | May 31, 2027 | MITCHELL, TANECIA R | reporter.nih.gov |
| Diffusion Histology Imaging: A Clinical Tool to Non-Invasively Diagnose and Manage Prostate Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,170,868 | January 1, 2022 | December 31, 2026 | IPPOLITO, JOSEPH EDWARD | reporter.nih.gov |
| Point-of-care antimicrobial susceptibility testing based on simultaneous tracking of multi-phenotypic features of single bacterial cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,159,472 | July 25, 2018 | June 30, 2025 | WANG, SHAOPENG | reporter.nih.gov |
| Functional Analysis of p53 Polymorphic Variants | NIH | National Cancer Institute | 2021 to 2025 | $2,158,835 | June 1, 2005 | November 30, 2026 | MURPHY, MAUREEN E. | reporter.nih.gov |
| Impact of the vaginal microbiome on Chlamydia trachomatis acquisition | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,158,356 | January 14, 2019 | December 31, 2025 | MCCLELLAND, RAYMOND SCOTT | reporter.nih.gov |
| Mechanisms of Prostate Cancer Metastasis | NIH | National Cancer Institute | 2021 to 2025 | $2,155,774 | September 17, 2021 | August 31, 2026 | FREEMAN, MICHAEL R. | reporter.nih.gov |
| An individualized medicine approach to urinary stone disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,155,309 | September 1, 2022 | November 30, 2026 | LIESKE, JOHN C | reporter.nih.gov |
| Regulation of cellular plasticity and regeneration in Drosophila spermatogenesis | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,153,352 | June 1, 2020 | March 31, 2030 | MATUNIS, ERIKA L | reporter.nih.gov |
| A non-canonical role for EZH2 in rRNA methtlation | NIH | National Cancer Institute | 2021 to 2025 | $2,146,235 | July 15, 2021 | June 30, 2026 | CAO, QI | reporter.nih.gov |
| Leveraging deep learning for markerless motion management in radiation therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,135,070 | April 1, 2021 | March 31, 2026 | XING, LEI | reporter.nih.gov |
| Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,132,323 | September 22, 2022 | August 31, 2027 | MOUW, KENT W | reporter.nih.gov |
| Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2024 | $2,114,450 | September 15, 2022 | May 31, 2027 | GRIFFITH, JAMES WILLIAM | reporter.nih.gov |
| Development of a novel biodegradable inorganic nanoparticle therapeutic for cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,113,155 | June 1, 2021 | May 31, 2026 | XIE, JIN | reporter.nih.gov |
| Regulation of extracellular vesicle biogenesis through cell adhesion | NIH | National Cancer Institute | 2021 to 2025 | $2,112,979 | April 6, 2020 | March 31, 2026 | PUA, HEATHER H | reporter.nih.gov |
| Impact of Menstruation on Chlamydial and Gonorrhea Infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,112,000 | September 22, 2025 | August 31, 2029 | KOHLMEIER, ALISON SWAIMS | reporter.nih.gov |
| Exercise as Interception Therapy in Primary High Risk Cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,107,239 | September 3, 2020 | June 30, 2026 | JONES, LEE W | reporter.nih.gov |
| A First-in-Class FAP-activated Protoxin to disrupt the Tumor-Stroma Parasitic Cycle fueling lethal Prostate Cancer Progression | NIH | National Cancer Institute | 2021 to 2025 | $2,103,278 | January 1, 2021 | December 31, 2025 | BRENNEN, WILLIAM NATHANIEL | reporter.nih.gov |
| Role of neuron-satellite glia cell signaling in pelvic pain and visceral cross-sensitization | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,081,882 | September 20, 2023 | July 31, 2028 | SUADICANI, SYLVIA OTTILIE | reporter.nih.gov |
| An AI-enabled Digital Pathology Platform for Multi-Cancer Diagnosis, Prognosis and Prediction of Therapeutic Benefit | NIH | National Cancer Institute | 2022 to 2025 | $2,081,138 | September 5, 2022 | August 31, 2027 | MADABHUSHI, ANANT | reporter.nih.gov |
| Preserving Erectile Function by Quantifying the Nerve-Sparing step of the Robotic Prostatectomy | NIH | National Cancer Institute | 2023 to 2025 | $2,077,876 | July 7, 2022 | June 30, 2027 | HUNG, ANDREW | reporter.nih.gov |
| Nitric Oxide-Soluble Guanylate Cyclase Pathway as a Target for Male Bladder Outlet Obstruction and Lower Urinary Tract Symptoms in Aging | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,068,975 | August 19, 2023 | June 30, 2027 | KANAI, ANTHONY JOHN | reporter.nih.gov |
| Understanding pathogen and host determinants of the natural history of N. gonorrhoeae infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,068,068 | June 23, 2023 | May 31, 2028 | DUNCAN, JOSEPH A | reporter.nih.gov |
| Leveraging whole-exome sequence data from diverse biobanks and cohorts to study rare coding variation in prostate cancer | NIH | National Cancer Institute | 2023 to 2025 | $2,067,626 | September 20, 2023 | August 31, 2028 | HAIMAN, CHRISTOPHER ALAN | reporter.nih.gov |
| Multiscale Computational Models Guided By Emerging Cellular Dynamics Quantification For Predicting Optimum Immune Checkpoint And Targeted Therapy Schedules | NIH | National Cancer Institute | 2021 to 2024 | $2,065,422 | May 1, 2020 | April 30, 2026 | JACKSON, TRACHETTE | reporter.nih.gov |
| Role of Urothelial Purinergic Signaling in Diabetic Bladder Dysfunction | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,061,868 | January 9, 2020 | September 14, 2028 | MUTAFOVA-YAMBOLIEVA, VIOLETA N. | reporter.nih.gov |
| Motor cortical neuromodulation in women with Interstitial Cystitis/Bladder Pain Syndrome: reducing pain by improving brain and muscle activity | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,060,111 | August 15, 2020 | April 30, 2026 | KUTCH, JASON J. | reporter.nih.gov |
| Optimizing Treatment of Prostate Cancer in Men living with HIV | NIH | National Cancer Institute | 2023 to 2025 | $2,059,152 | August 1, 2023 | June 30, 2028 | SIGEL, KEITH MAGNUS | reporter.nih.gov |
| A Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Testicular Cancer Survivors | NIH | National Cancer Institute | 2023 to 2025 | $2,056,218 | July 8, 2023 | June 30, 2028 | HOYT, MICHAEL A | reporter.nih.gov |
| Randomized Trial of Exercise Therapy on Markers of Progression in Localized Prostate Cancer: | NIH | National Cancer Institute | 2022 to 2024 | $2,054,025 | September 15, 2022 | July 31, 2027 | JONES, LEE W | reporter.nih.gov |
| Clinical Feasibility of Wireless Catheter-Free Urodynamics for Extended, Comprehensive Urological Evaluation in the Home Setting | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $2,051,654 | March 1, 2023 | July 31, 2024 | HERRERA, DEREK | reporter.nih.gov |
| Cystitis-induced bladder dysfunction and pain | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,050,607 | January 28, 2021 | December 31, 2025 | VIZZARD, MARGARET ANN | reporter.nih.gov |
| MRI Virtual Pathology of the Prostate: Multi-center multi-vendor application and validation | NIH | National Cancer Institute | 2022 to 2023 | $2,049,960 | April 1, 2020 | June 30, 2026 | OTO, AYTEKIN | reporter.nih.gov |
| A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC) | NIH | National Cancer Institute | 2023 to 2025 | $2,048,902 | July 7, 2023 | June 30, 2027 | SCHULER, AARON D | reporter.nih.gov |
| KULMAP: Human Kidney, urinary tract and lung mapping center | NIH | National Heart, Lung, and Blood Institute | 2021 | $2,048,510 | September 25, 2018 | December 31, 2022 | ZHANG, KUN | reporter.nih.gov |
| Estrogen pathways in the development of prostatic fibrosis and lower urinary tract dysfunction | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,046,099 | April 1, 2021 | March 31, 2026 | RICKE, WILLIAM A | reporter.nih.gov |
| 3D Spatial Biology of Prostate Cancer Biopsies For Earlier Identification of High Risk Patients | NIH | National Cancer Institute | 2024 to 2025 | $2,045,816 | September 5, 2020 | June 30, 2027 | REDER, NICHOLAS | reporter.nih.gov |
| Intensive cholesterol-lowering intervention and anti-tumor immunity modeled in prostate cancer | NIH | National Cancer Institute | 2023 to 2025 | $2,041,405 | September 21, 2023 | August 31, 2028 | KIM, HYUNG L | reporter.nih.gov |
| Development of a mechanistically novel Gram-negative antibiotic targeting MsbA-mediated Lipopolysaccharide Biogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,038,369 | November 4, 2022 | October 31, 2027 | ROEMER, TERRY | reporter.nih.gov |
| Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression: A double-blind randomized controlled trial | NIH | National Cancer Institute | 2023 to 2025 | $2,036,734 | September 1, 2023 | August 31, 2028 | COLETTA, ADRIANA | reporter.nih.gov |
| Cellular and molecular mechanisms of vertebrate testis homeostasis | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,031,663 | August 1, 2021 | July 31, 2026 | GAGNON, JAMES ALAN | reporter.nih.gov |
| Central Sensitization and Psychosocial Impacts on Overactive Bladder | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,022,106 | September 24, 2021 | July 31, 2025 | SEBESTA, ELISABETH M | reporter.nih.gov |
| Molecular Insights into the Uropathogenesis of MDR Acinetobacter baumannii | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,021,352 | February 6, 2019 | January 31, 2025 | FELDMAN, MARIO | reporter.nih.gov |
| Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,021,205 | April 9, 2021 | March 31, 2027 | GIUS, DAVID | reporter.nih.gov |
| Single-Cell Analysis of the Noncoding Genome in Human Diseases and Evolution | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,018,750 | August 13, 2021 | June 30, 2027 | LI, JINGJING | reporter.nih.gov |
| Molecular mechanisms of uropathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,017,860 | August 1, 2005 | June 30, 2025 | PEARSON, MELANIE M. | reporter.nih.gov |
| Pilot study of an implantable microdevice to test multiple drug responses in prostate cancer patients | NIH | National Cancer Institute | 2021 to 2023 | $2,012,150 | March 4, 2019 | February 28, 2025 | JONAS, OLIVER | reporter.nih.gov |
| Androgen receptor pathway inhibition through targeting PARP-2 in castration-resistant prostate cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,010,462 | July 1, 2021 | June 30, 2026 | JIA, LI | reporter.nih.gov |
| Optimization of urinary DNA deep sequencing tests to enhance clinical staging of bladder cancer patients | NIH | National Cancer Institute | 2021 to 2025 | $2,009,718 | August 1, 2021 | July 31, 2027 | ABBOSH, PHILIP | reporter.nih.gov |
| Specificity of regulatory T cell suppression during infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,009,680 | May 1, 2021 | April 30, 2026 | SAVAGE, PETER AIDAN | reporter.nih.gov |
| Improving cancer-related fatigue, sexual dysfunction and quality of life in older men with cancer and androgen deficiency | NIH | National Institute on Aging | 2021 to 2025 | $2,009,234 | August 1, 2019 | April 30, 2027 | GARCIA, JOSE M. | reporter.nih.gov |
| Functional analysis of novel testis-expressed secreted and transmembrane proteins | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $2,008,380 | August 1, 2016 | March 31, 2027 | MATZUK, MARTIN M. | reporter.nih.gov |
| Systems analysis of aggressive prostate cancer pathology | NIH | National Cancer Institute | 2021 to 2023 | $2,003,318 | September 1, 2019 | August 31, 2025 | COSTELLO, JAMES CHRISTOPHER | reporter.nih.gov |
| Molecular origins and evolution to chemoresistance in germ cell tumors | NIH | National Cancer Institute | 2021 to 2024 | $2,002,931 | February 1, 2023 | January 31, 2025 | VAN ALLEN, ELIEZER M | reporter.nih.gov |
| Ultrasound-based diagnostic and monitoring of bladder cancer treatment with drug released from nanoparticles | NIH | National Cancer Institute | 2021 to 2022 | $2,000,000 | September 7, 2018 | August 31, 2025 | ASSOULINE, JOE | reporter.nih.gov |
| Development of a Commercial-Ready Kit for CTT1403, a Novel PSMA-Targeted Radiotherapy | NIH | National Cancer Institute | 2021 to 2022 | $2,000,000 | September 20, 2021 | August 31, 2024 | BOMBA, HUNTER NICOLE | reporter.nih.gov |
| Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer | NIH | National Cancer Institute | 2022 to 2023 | $2,000,000 | September 14, 2022 | August 31, 2025 | GAO, SONGQI | reporter.nih.gov |
| Development of a Therapeutic SAPNANO-ESO Vaccine for Prostate Cancer | NIH | National Cancer Institute | 2022 to 2023 | $2,000,000 | August 1, 2022 | July 31, 2026 | WANG, YICHENG | reporter.nih.gov |
| Programming Metabolically Fit TILs for Immunotherapy | NIH | National Cancer Institute | 2023 to 2024 | $2,000,000 | February 15, 2020 | August 31, 2025 | MEHROTRA, SHIKHAR | reporter.nih.gov |
| New oral antibiotics focused on treating MDR Gram-negative infections | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,000,000 | July 9, 2024 | June 30, 2027 | TESTA, CHARLES | reporter.nih.gov |
| Toxicology (IND-enabling) studies for a novel nerve imaging agent for prostate cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,996,496 | September 6, 2024 | August 31, 2026 | KAHL, STEPHEN B | reporter.nih.gov |
| Cross Organ Mechanisms in Chronic Pelvic Pain | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,992,227 | May 15, 2023 | March 31, 2028 | TU, FRANK FU-SHENG | reporter.nih.gov |
| HLA-E and NKG2A define a novel immune checkpoint axis in non-muscle-invasive bladder cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,990,656 | February 1, 2023 | January 31, 2028 | HOROWITZ, AMIR | reporter.nih.gov |
| Function of the Stem Cell Transcription Factor SOX2 in Prostatic Enlargement | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,988,247 | March 10, 2020 | December 31, 2025 | VANDER GRIEND, DONALD JAMES | reporter.nih.gov |
| Comprehensive Assessment of Cancer Theranostics Response | NIH | National Cancer Institute | 2023 to 2024 | $1,985,840 | September 22, 2023 | August 31, 2025 | PERK, TIMOTHY | reporter.nih.gov |
| Characterizing the binding mechanisms of castration-resistant prostate cancer therapeutics to the intrinsically disordered N-terminal domain of the androgen receptor | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,979,921 | September 15, 2021 | June 30, 2026 | ROBUSTELLI, PAUL | reporter.nih.gov |
| Determining the clinical impact of gene expression testing in localized prostate cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,978,776 | September 1, 2019 | August 31, 2025 | MORGAN, TODD M. | reporter.nih.gov |
| Cellular and Molecular Basis of Sex Specificity in UTI Pathogenesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,975,613 | September 15, 2020 | July 31, 2025 | HUNSTAD, DAVID | reporter.nih.gov |
| Low-Cost Instrument-free Point-of-Care Test for Chlamydia and Gonorrhea | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,974,336 | April 22, 2020 | March 31, 2024 | SINGH, SHEENA DEVIKA | reporter.nih.gov |
| Stress and Anxiety Effects on Overactive Bladder: A Controlled Study | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,973,971 | September 15, 2021 | July 31, 2027 | SEBESTA, ELISABETH M | reporter.nih.gov |
| Molecular regulation and expression of Trop-2 in advanced prostate cancer: Identifying optimal therapeutic niches | NIH | National Cancer Institute | 2023 to 2025 | $1,972,155 | July 1, 2023 | June 30, 2028 | LANG, JOSHUA | reporter.nih.gov |
| Targeting Non-Canonical STING Signaling to Treat SPOP Mutant Castration-Resistant Prostate Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,971,553 | September 19, 2023 | August 31, 2028 | THOMPSON, TIMOTHY CHARLES | reporter.nih.gov |
| (PQ11) Immune modulatory effects of white button mushroom in prostate cancer - A translational research | NIH | National Cancer Institute | 2021 to 2023 | $1,970,965 | September 1, 2019 | August 31, 2025 | CHEN, SHIUAN | reporter.nih.gov |
| Novel Type 1 Pilus Receptors in Pyelonephritis and Recurrent UTI | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,968,750 | April 1, 2021 | March 31, 2027 | HUNSTAD, DAVID | reporter.nih.gov |
| Prostate Cancer Vulnerabilities to BH3 Mimetic Drugs | NIH | National Cancer Institute | 2021 to 2025 | $1,965,536 | June 1, 2021 | May 31, 2026 | BALK, STEVEN P. | reporter.nih.gov |
| BEST CARE for Recurrent NMIBC: BladdEr-Sparing Therapy and Cystectomy As TREatments | NIH | National Cancer Institute | 2024 to 2025 | $1,965,224 | July 1, 2024 | June 30, 2029 | GORE, JOHN L. | reporter.nih.gov |
| Multiplexed Assay for Point-of-Care UTI Diagnosis (ID/AMR) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,961,669 | March 1, 2024 | February 28, 2027 | BURKLUND, ALISON | reporter.nih.gov |
| Systematic evaluation of toxicity and therapeutic efficacy in CD46 directed radioligand therapy | NIH | National Cancer Institute | 2023 to 2025 | $1,959,827 | May 1, 2023 | April 30, 2028 | FLAVELL, ROBERT RICHARD | reporter.nih.gov |
| Clinical readiness of Uzap - the minimally invasive Overactive Bladder treatment | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,959,549 | September 20, 2021 | June 30, 2025 | STERN, ROGER | reporter.nih.gov |
| Breaking the Scope Port Size Barrier: A New Kind of Endoscope that Removes Large Kidney Stones Rapidly | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2024 | $1,957,949 | August 1, 2023 | June 30, 2026 | GAFFORD, JOSHUA B | reporter.nih.gov |
| A novel strategy to overcome drug resistance in cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,956,732 | March 1, 2021 | February 28, 2027 | EDINGER, AIMEE L | reporter.nih.gov |
| Germline Determinants of Prostate Cancer Evolution | NIH | National Cancer Institute | 2023 to 2025 | $1,954,844 | April 1, 2023 | March 31, 2028 | SPELLMAN, PAUL T. | reporter.nih.gov |
| Optimizing prostate cancer care: integrating risks, benefits, and patient experiences in the new era of molecular imaging | NIH | National Cancer Institute | 2023 to 2025 | $1,950,868 | September 13, 2023 | August 31, 2028 | LEAPMAN, MICHAEL STUART | reporter.nih.gov |
| Impact of Foreign Bodies on Infection Susceptibility, Disease and Mucosal Remodeling of the Urinary Tract | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,947,026 | January 1, 1997 | December 31, 2027 | HULTGREN, SCOTT J. | reporter.nih.gov |
| Continuous Monitoring and Management of Vaginal Health via Multifunctional OCT/OCTA Endoscopy | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 | $1,946,945 | September 15, 2021 | September 14, 2025 | CHEN, ZHONGPING | reporter.nih.gov |
| Interleukin-1beta and AR-negative tumor cells in metastatic castrate-resistant prostate cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,945,498 | September 1, 2022 | August 31, 2027 | FATATIS, ALESSANDRO | reporter.nih.gov |
| Neuroimmune Interface in Urological Chronic Pelvic Pain Syndrome | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,945,113 | January 22, 2020 | November 30, 2025 | HARTE, STEVEN EDWARD | reporter.nih.gov |
| Control of lethal prostate cancer with a bispecific av and a5b1 integrin antibody | NIH | National Cancer Institute | 2021 to 2024 | $1,936,422 | June 1, 2020 | May 31, 2026 | MATHEW, PAUL | reporter.nih.gov |
| An integrative multi-omics approach to characterize prostate cancer risk in diverse populations | NIH | National Cancer Institute | 2021 to 2024 | $1,935,577 | July 16, 2021 | June 30, 2027 | MANCUSO, NICHOLAS | reporter.nih.gov |
| Targeting the colchicine binding site in tubulin for cancer therapy | NIH | National Cancer Institute | 2021 to 2025 | $1,935,287 | January 1, 2011 | December 31, 2026 | LI, WEI | reporter.nih.gov |
| Small-molecule therapy for metastatic castration-resistant prostate cancer | NIH | National Cancer Institute | 2021 to 2022 | $1,935,175 | August 1, 2017 | August 31, 2025 | WU, DAQING | reporter.nih.gov |
| Registering Cancer Recurrences in the Georgia Cancer Registry | NIH | National Cancer Institute | 2021 to 2024 | $1,933,624 | February 15, 2019 | July 31, 2025 | WARD, KEVIN C | reporter.nih.gov |
| Hyperpolarized C-13 MRI for Early Detection of Aggressive Prostate Cancer in Active Surveillance Patients | NIH | National Cancer Institute | 2021 to 2023 | $1,932,408 | April 11, 2019 | March 31, 2025 | VIGNERON, DANIEL B | reporter.nih.gov |
| A Prospective Randomized Controlled Trial to Evaluate the Impact of Treatment of Asymptomatic Bacteriuria on Low Birth Weight | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $1,929,206 | September 20, 2024 | August 31, 2028 | MCCLURE, ELIZABETH M | reporter.nih.gov |
| Targeting the microtubule cytoskeleton to promote cavernous nerve regeneration and erectile function after injury | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,928,183 | September 1, 2023 | June 30, 2028 | DAVIES, KELVIN P | reporter.nih.gov |
| A Digital Twin for Designing Bladder Treatment informed by Bladder Outlet Obstruction Mechanobiology (BOOM) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,925,422 | August 11, 2023 | July 31, 2028 | ROBERTSON, ANNE MARIE | reporter.nih.gov |
| Androgen Signaling in CaP with loss of MAP3K7 and CHD1 | NIH | National Cancer Institute | 2021 to 2025 | $1,924,438 | July 1, 2021 | June 30, 2026 | CRAMER, SCOTT D | reporter.nih.gov |
| Improving Quality of Life of Prostate Cancer Survivors with Androgen Deficiency | NIH | National Institute on Aging | 2021 to 2023 | $1,923,916 | August 1, 2018 | September 30, 2025 | BHASIN, SHALENDER | reporter.nih.gov |
| Polygenic risk stratification combined with mpMRI to identify clinically relevant prostate cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,922,720 | April 12, 2023 | March 31, 2028 | KIBEL, ADAM S | reporter.nih.gov |
| "DNMT and TET1 reprogramming as a targetable mechanism of resistance in advanced prostate cancer" | NIH | National Cancer Institute | 2023 to 2025 | $1,921,654 | June 1, 2023 | May 31, 2028 | RICKMAN, DAVID S. | reporter.nih.gov |
| Derivation of Functional Spermatogonia Stem Cells from Rhesus Macaque iPSCs | NIH | Office of the Director, National Institutes of Health | 2021 to 2022 | $1,921,633 | September 9, 2019 | June 30, 2024 | EASLEY, CHARLES A. | reporter.nih.gov |
| Improving Patient-Important Outcomes with Testosterone Replacement in Hypogonadal Men with a Prior History of Cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,917,613 | May 8, 2019 | April 30, 2027 | GARCIA, JOSE M. | reporter.nih.gov |
| Mechanisms governing metastatic dormancy and reactivation | NIH | National Cancer Institute | 2021 to 2022 | $1,915,493 | August 1, 2016 | July 31, 2023 | GIANCOTTI, FILIPPO G | reporter.nih.gov |
| Drug Development of Skp2 PROTACs in Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,912,388 | May 31, 2023 | April 30, 2028 | LI, HONG-YU | reporter.nih.gov |
| Microendoscopic Electrical Impedance Sensing for Real-time Intraoperative Surgical Margin Assessment | NIH | National Cancer Institute | 2021 to 2024 | $1,910,965 | July 15, 2020 | June 30, 2025 | HALTER, RYAN JOSEPH | reporter.nih.gov |
| AR Gene Rearrangements and AR Signaling in Prostate Cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,909,771 | April 1, 2013 | March 31, 2028 | DEHM, SCOTT M. | reporter.nih.gov |
| Rapid and flexible precision oncology mouse models of epithelial malignancies epithelial malignancies | NIH | National Cancer Institute | 2021 to 2024 | $1,908,434 | January 1, 2020 | December 31, 2024 | LOWE, SCOTT W. | reporter.nih.gov |
| Ligand-mediated, vehicle-free delivery of small RNAs | NIH | National Cancer Institute | 2021 to 2025 | $1,908,192 | April 1, 2018 | August 31, 2028 | KASINSKI, ANDREA L | reporter.nih.gov |
| Deciphering Mechanisms of Tumor-Stromal Interactions in Prostate Cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,908,093 | May 1, 2021 | April 30, 2027 | WU, BOYANG | reporter.nih.gov |
| Distinct Tumor and Metastatic Collagen Microenvironments: Divergent Targeting Approaches | NIH | National Cancer Institute | 2023 to 2025 | $1,906,818 | September 30, 2013 | April 30, 2026 | CHAN, KEITH SYSON | reporter.nih.gov |
| Targeting Mitochondrial Redox Capacity to Overcome Cancer Subtype that Regrowth After Radiation | NIH | National Cancer Institute | 2021 to 2025 | $1,906,181 | April 1, 2021 | March 31, 2027 | CHAISWING, LUKSANA | reporter.nih.gov |
| Mechanisms of metabolic stress-induced transcriptional regulation in prostate cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,900,860 | April 1, 2021 | March 31, 2027 | DASGUPTA, SUBHAMOY | reporter.nih.gov |
| Bladder cancer PD-L1 control of homologous recombination: Basic mechanisms applied to novel treatments | NIH | National Cancer Institute | 2022 to 2025 | $1,900,808 | September 1, 2022 | February 29, 2028 | CURIEL, TYLER J. | reporter.nih.gov |
| "Novel Mouse Models for Quantitative Understanding of Baseline and Therapy-Driven Evolution of Prostate Cancer Metastasis" | NIH | National Cancer Institute | 2023 to 2025 | $1,899,979 | April 1, 2023 | March 31, 2028 | NOWAK, DAWID GRZEGORZ | reporter.nih.gov |
| Effects of TNF Blockade on Human BPH/LUTS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,899,179 | August 15, 2023 | May 31, 2028 | HAYWARD, SIMON W | reporter.nih.gov |
| Discriminatory Mechanisms in Early-Onset and Lethal Prostate Cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,894,111 | August 13, 2021 | July 31, 2026 | COHN, BARBARA A | reporter.nih.gov |
| Establishing and Mimicking Patterning Mechanisms in the Distal Nephron Tubule and Kidney Organoid | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,891,016 | August 1, 2023 | June 30, 2028 | LINDSTROM, NILS OLOF | reporter.nih.gov |
| Enhancement of tumor radiation response by ultrasound-driven nanobubble stimulation | NIH | National Cancer Institute | 2021 to 2024 | $1,889,708 | August 11, 2021 | July 31, 2026 | EXNER, AGATA A | reporter.nih.gov |
| Functional Analysis of Structure Specific Nucleases in Genome Stability and Cancers | NIH | National Cancer Institute | 2021 to 2025 | $1,887,170 | September 20, 2016 | August 31, 2026 | ZHENG, LI | reporter.nih.gov |
| Racially-associated MRI analysis and modeling for predicting aggressive prostate cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,884,679 | September 15, 2023 | August 31, 2028 | SUNG, KYUNG HYUN | reporter.nih.gov |
| Breaking down tumor immune privilege through targeted hypoxia reduction | NIH | National Cancer Institute | 2021 to 2024 | $1,883,414 | July 1, 2020 | June 30, 2025 | CURRAN, MICHAEL A. | reporter.nih.gov |
| Transformation of Dormant Spinal Networks to Mitigate Symptoms of Neurogenic Bladder | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $1,881,342 | August 15, 2021 | July 31, 2024 | GAD, PARAG | reporter.nih.gov |
| Inside-Out Nonlinear Gradients to Improve Diffusion MRI | NIH | National Cancer Institute | 2021 to 2025 | $1,881,297 | July 6, 2021 | September 30, 2026 | GALIANA, GIGI | reporter.nih.gov |
| Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC) | NIH | National Cancer Institute | 2023 to 2025 | $1,877,904 | September 21, 2023 | August 31, 2028 | APARICIO, ANA | reporter.nih.gov |
| Statistical methods for genomic analysis of heterogeneous tumors | NIH | National Cancer Institute | 2022 to 2025 | $1,872,847 | July 8, 2022 | June 30, 2027 | WANG, WENYI | reporter.nih.gov |
| Therapeutic targeting Wnt5A signaling for advanced prostate cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,872,645 | December 1, 2020 | November 30, 2026 | GAO, ALLEN C. | reporter.nih.gov |
| Understanding the role of catheter-associated protein deposition in the development of CAUTI | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,872,330 | May 1, 2021 | February 28, 2027 | FLORES-MIRELES, ANA LIDIA | reporter.nih.gov |
| Comprehensive characterization of prostate stromal gene expression and association with lethal prostate cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,871,496 | February 1, 2023 | January 31, 2026 | BIRMANN, BRENDA M | reporter.nih.gov |
| Genetics of human renal hypodysplasia | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,871,360 | April 1, 2008 | May 31, 2025 | GHARAVI, ALI G | reporter.nih.gov |
| Targeting the Plk1/Pdcd4/mTORC2 Signaling to Treat Castration-Resistant Prostate Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,867,088 | July 1, 2023 | June 30, 2028 | LIU, XIAOQI | reporter.nih.gov |
| Understanding the influence of bone-metastatic prostate cancer and mesenchymal stromal cells on γδ T cells, in the bone microenvironment. | NIH | National Cancer Institute | 2021 to 2024 | $1,866,870 | March 9, 2020 | August 31, 2025 | ABATE-DAGA, DANIEL | reporter.nih.gov |
| Drug Eluting Silk Fibroin Grafts for Repair of Long Urethral Strictures | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,864,246 | February 15, 2023 | December 31, 2026 | MAUNEY, JOSHUA ROBERT | reporter.nih.gov |
| Sensory Cross-Activation in Bowel Dysfunction | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,863,243 | December 15, 2021 | November 30, 2026 | QIAO, LIYA | reporter.nih.gov |
| Long-Term Adverse Outcomes Among Rural Cancer Survivors in a Population-Based Cohort | NIH | National Cancer Institute | 2021 to 2024 | $1,858,613 | July 16, 2020 | June 30, 2025 | CAMP, NICOLA J. | reporter.nih.gov |
| Physician dispensing of oral specialty drugs for advanced prostate cancer and its implications for patients | NIH | National Cancer Institute | 2023 to 2025 | $1,856,603 | February 1, 2023 | August 31, 2028 | HOLLENBECK, BRENT K. | reporter.nih.gov |
| The Clinical History of Rectal and Urethral STIs among MSM: characterizing microbiome host immune interactions for diagnostic and vaccine advances | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,855,034 | August 1, 2025 | July 31, 2028 | MEHTA, SUPRIYA DINESH | reporter.nih.gov |
| Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER) | NIH | National Cancer Institute | 2021 to 2024 | $1,853,377 | February 15, 2019 | January 31, 2026 | HAHN, NOAH M | reporter.nih.gov |
| Endothelial Epoxygenase, Kidney Injury, and Blood Pressure Regulation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,853,087 | June 1, 2021 | May 31, 2027 | IMIG, JOHN D | reporter.nih.gov |
| Overcoming vaccine-associated hypoxia with advanced biomaterials to enhance cancer immunotherapy | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $1,852,300 | July 1, 2021 | March 31, 2026 | HATFIELD, STEPHEN MATTHEW | reporter.nih.gov |
| RSI-AI: Predicting clinically significant prostate cancer to guide biopsy decisions by combining advanced tissue microstructure imaging with deep learning | NIH | National Cancer Institute | 2021 to 2024 | $1,847,999 | August 15, 2021 | July 31, 2025 | WHITE, NATHAN SCOTT | reporter.nih.gov |
| PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREV | NIH | National Cancer Institute | 2021 to 2024 | $1,847,366 | September 8, 2020 | March 31, 2025 | MCCORMICK, DAVID | reporter.nih.gov |
| Development of Next-Generation Blood-to-barcode (B2B) chip for In Vivo CRISPR-Based Discovery of Metastasis Regulators | NIH | National Cancer Institute | 2023 to 2025 | $1,846,447 | February 7, 2023 | January 31, 2028 | KELLEY, SHANA O | reporter.nih.gov |
| Decoding tumor metabolic and immunologic interactions driving different biological subtypes in patients with bladder cancer. | NIH | National Cancer Institute | 2023 to 2025 | $1,845,432 | July 1, 2023 | June 30, 2028 | PUTLURI, NAGIREDDY | reporter.nih.gov |
| Prevention of LUTS: Bladder Health Clinical Center, UC San Diego Site | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,840,216 | August 15, 2015 | June 30, 2025 | LUKACZ, EMILY S. | reporter.nih.gov |
| TLR Transduction of Dysbiotic Pelvic Pain | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,838,981 | August 21, 2023 | June 30, 2027 | KLUMPP, DAVID J | reporter.nih.gov |
| High throughput infrastructure for reaction screening and bioassays | NIH | National Center for Advancing Translational Sciences | 2022 to 2023 | $1,838,646 | June 1, 2022 | May 31, 2024 | COOKS, ROBERT GRAHAM | reporter.nih.gov |
| Addressing Circulation of Guideline-Discordant Information to Promote Optimal Prostate Cancer Care | NIH | National Cancer Institute | 2023 to 2025 | $1,837,936 | February 7, 2023 | January 31, 2028 | LOEB, STACY | reporter.nih.gov |
| Mucosal Immune Defense Mechanisms of the Urinary Bladder | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,837,095 | February 15, 2023 | December 31, 2027 | COLONNA, MARCO | reporter.nih.gov |
| High-throughput Clinical Hyperpolarized 13C MRI | NIH | Office of the Director, National Institutes of Health | 2025 | $1,835,840 | August 1, 2025 | July 1, 2027 | TSAI, LEO LEE | reporter.nih.gov |
| Prostate cancer risk stratification via computational 3D pathology | NIH | National Cancer Institute | 2022 to 2024 | $1,831,816 | July 1, 2022 | June 30, 2027 | LIU, JONATHAN T.C. | reporter.nih.gov |
| A New Immune Checkpoint Pathway in Human Bladder Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,831,518 | December 1, 2022 | November 30, 2027 | ZANG, XINGXING | reporter.nih.gov |
| Investigation of brain mechanisms involved in Urgency Urinary Incontinence | NIH | National Institute on Aging | 2021 to 2024 | $1,830,027 | September 15, 2019 | March 31, 2026 | CLARKSON, BECKY D | reporter.nih.gov |
| Sleep and Bladder Study | NIH | National Institute on Aging | 2022 to 2025 | $1,828,940 | August 1, 2022 | January 31, 2027 | TYAGI, SHACHI | reporter.nih.gov |
| Rigorous and reproducible mutational analysis of the urinary exosomal DNA | NIH | National Cancer Institute | 2021 to 2023 | $1,825,912 | July 1, 2019 | June 30, 2025 | KALLURI, RAGHU | reporter.nih.gov |
| Rapid phage-amplified immunoassay for phenotypic UTI diagnosis and antimicrobial susceptibility testing | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2023 | $1,825,667 | September 17, 2020 | August 31, 2025 | COX, CHRISTOPHER R | reporter.nih.gov |
| Impact of Aging on Mucosal Immune Protection in the Female Reproductive | NIH | National Institute on Aging | 2021 to 2023 | $1,824,844 | March 1, 2019 | December 31, 2024 | WIRA, CHARLES ROBERT | reporter.nih.gov |
| Elevated homocysteine in African American Prostate Cancer: Association with Diet and Dietary practices, evaluating its biomarker potential, and characterizing its tumor promoting function | NIH | National Cancer Institute | 2022 to 2025 | $1,824,802 | April 1, 2022 | March 31, 2027 | SREEKUMAR, ARUN | reporter.nih.gov |
| Biomarker-Based Tools for Treatment Response Decision Support of Bladder Cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,824,103 | May 6, 2019 | April 30, 2025 | HADJIYSKI, LUBOMIR M | reporter.nih.gov |
| Identifying lethal prostate cancer at diagnosis with advanced proteoglycomic, radiomic, and genomic approaches | NIH | National Cancer Institute | 2023 to 2025 | $1,823,701 | July 7, 2023 | June 30, 2028 | IPPOLITO, JOSEPH EDWARD | reporter.nih.gov |
| A Robotic System to Remove Bladder Tumors Intact: The Key to Making Lifesaving Treatment Decisions | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 to 2024 | $1,822,114 | September 9, 2023 | August 31, 2025 | HENDRICK, RICHARD JOSEPH | reporter.nih.gov |
| T32 Urologic Oncology Research Training Grant | NIH | National Cancer Institute | 2021 to 2025 | $1,820,315 | September 1, 1999 | July 31, 2030 | CARVER, BRETT STEWART | reporter.nih.gov |
| Targeting m6A RNA epigenetics in treatment-emergent neuroendocrine prostate cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,819,525 | June 4, 2021 | November 30, 2026 | SONG, MIN SUP | reporter.nih.gov |
| Diversification of cell types during male and female external genital development | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,815,494 | September 30, 2021 | July 31, 2026 | COHN, MARTIN J | reporter.nih.gov |
| eRapa for bladder cancer prevention | NIH | National Cancer Institute | 2021 to 2024 | $1,813,363 | July 1, 2020 | June 30, 2026 | SVATEK, ROBERT SCOTT | reporter.nih.gov |
| The role of acetogenic, methanogenic, and sulfate-reducing bacteria in oxalate metabolism and hyperoxaluria | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,811,784 | April 17, 2020 | February 28, 2026 | MILLER, AARON W | reporter.nih.gov |
| NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,810,625 | May 22, 2019 | April 30, 2026 | GOODRICH, DAVID W. | reporter.nih.gov |
| Targeting alternative splicing for TCR discovery in small cell carcinomas | NIH | National Cancer Institute | 2021 to 2022 | $1,809,996 | September 21, 2018 | August 31, 2024 | WITTE, OWEN N. | reporter.nih.gov |
| Noninvasive histotripsy ablation of fibrotic tissue in benign prostatic hyperplasia | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,809,731 | September 1, 2019 | June 30, 2025 | SCHADE, GEORGE R | reporter.nih.gov |
| 3-Way Approach for ED Prevention | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,809,631 | September 1, 2014 | June 30, 2025 | PODLASEK, CAROL ANN | reporter.nih.gov |
| Extension of Urinary Stone Disease Research Network (USDRN) at Washington University | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2024 | $1,808,026 | September 1, 2016 | August 31, 2025 | LAI, HING HUNG HENRY | reporter.nih.gov |
| An urinary drug disposing approach for treatment of bladder Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,808,016 | July 13, 2023 | June 30, 2028 | LAW, BENEDICT SHEK HANG | reporter.nih.gov |
| Identifying and Reducing Disparities in Patient-Reported Outcomes Among African American Prostate Cancer Survivors | NIH | National Cancer Institute | 2021 to 2024 | $1,806,535 | July 23, 2020 | June 30, 2026 | GONZALEZ, BRIAN D | reporter.nih.gov |
| Development of Methods for a Simplified and Reliable Prostate Cancer MRI Exam | NIH | National Cancer Institute | 2021 to 2025 | $1,799,393 | June 1, 2020 | November 30, 2026 | MAIER, STEPHAN E | reporter.nih.gov |
| Adaptive Percutaneous Prostate Interventions using Sensorized Needle | NIH | National Cancer Institute | 2021 to 2025 | $1,799,242 | August 1, 2019 | February 29, 2028 | TOKUDA, JUNICHI | reporter.nih.gov |
| Defining the role of isoprenylated xanthones from the mangosteen for enhancing degradation of full length and variant forms of androgen receptor in prostate cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,796,578 | January 1, 2019 | April 30, 2027 | JOHNSON, JEREMY JAMES | reporter.nih.gov |
| Phase II Clinical trial of GTC in Men on Active Surveillance | NIH | National Cancer Institute | 2021 to 2024 | $1,792,639 | June 1, 2019 | May 31, 2026 | KUMAR, NAGI B. | reporter.nih.gov |
| Stromal Foxf2 suppresses prostate cancer progression | NIH | National Cancer Institute | 2022 to 2025 | $1,790,773 | July 1, 2022 | May 31, 2027 | XIN, LI | reporter.nih.gov |
| 10-year Comparative Effectiveness and Harms of Treatments for Prostate Cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,788,766 | April 1, 2019 | December 31, 2024 | BAROCAS, DANIEL A | reporter.nih.gov |
| Biomarkers of Sulforaphane/Broccoli Sprout Extract in Prostate Cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,788,361 | January 1, 2019 | December 31, 2024 | SINGH, SHIVENDRA | reporter.nih.gov |
| Tailored prostate cancer screening: addressing USPSTF priority research gaps in a racially-diverse study population | NIH | National Cancer Institute | 2023 to 2025 | $1,787,388 | August 1, 2023 | July 31, 2028 | LANGSTON, MARVIN EPOLIAN | reporter.nih.gov |
| Molecular Mechanisms of Castration Resistant Prostate Cancer Recurrence & Therapeutic Strategies | NIH | National Cancer Institute | 2021 to 2023 | $1,784,465 | December 14, 2018 | November 30, 2023 | MAHAJAN, NUPAM P | reporter.nih.gov |
| Impact of Inflammation on Adult Prostate Stem Cells | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,784,241 | August 1, 2020 | June 30, 2025 | RATLIFF, TIMOTHY L. | reporter.nih.gov |
| Evaluation of Pre-Analytical Factors of Urine Samples for Urine Cancer Cell Cultures (UCCC) --A Non-Invasive Biomarker – in Monitoring Response and Recurrence of Bladder Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,783,393 | September 6, 2023 | August 31, 2028 | LIU, XUEFENG | reporter.nih.gov |
| Modulating HSP70/STUB1 machinery in therapy-resistant prostate cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,783,175 | September 1, 2021 | August 31, 2026 | LIU, CHENGFEI | reporter.nih.gov |
| Advanced Training in Urologic Oncology | NIH | National Cancer Institute | 2021 to 2025 | $1,781,697 | August 22, 2014 | June 30, 2029 | PALAPATTU, GANESH S | reporter.nih.gov |
| Role of PIEZO Channels in Bladder Function and Dysfunction | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,780,998 | August 1, 2019 | May 31, 2025 | APODACA, GERARD L | reporter.nih.gov |
| Advanced PET-CT Directed Post-Prostatectomy Radiotherapy to Enhance Prostate Cancer Outcomes | NIH | National Cancer Institute | 2021 to 2023 | $1,778,839 | May 1, 2019 | April 30, 2025 | JANI, ASHESH | reporter.nih.gov |
| Intraoperative integration of artificial intelligence during cystoscopic surgery | NIH | National Cancer Institute | 2022 to 2025 | $1,775,432 | January 1, 2022 | December 31, 2027 | LIAO, JOSEPH C | reporter.nih.gov |
| Dissecting the Role of Proteostasis in Anti-Androgen Resistant Prostate Cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,770,550 | July 1, 2021 | June 30, 2026 | LIU, CHENGFEI | reporter.nih.gov |
| A novel AR degrader in castrate-resistant prostate cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,765,881 | August 15, 2023 | June 30, 2028 | KIM, HYEONG-REH CHOI | reporter.nih.gov |
| Defining bone ecosystem effects on metastatic prostate cancer evolution and treatment response using an integrated mathematical modeling approach | NIH | National Cancer Institute | 2021 to 2024 | $1,758,201 | June 11, 2020 | May 31, 2025 | LYNCH, CONOR C | reporter.nih.gov |
| Mechanism and Therapeutic Targeting of TRIM29-mediated Invasion in Bladder Cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,755,325 | August 1, 2022 | July 31, 2027 | PALMBOS, PHILLIP L | reporter.nih.gov |
| Evaluating prostate cancer phenotype and genotype classification from circulating tumor DNA as biomarkers for predicting treatment outcomes | NIH | National Cancer Institute | 2023 to 2025 | $1,755,220 | September 19, 2023 | August 31, 2028 | HA, GAVIN | reporter.nih.gov |
| Glycosylation and Immune Evasion in Urologic Tumors | NIH | National Cancer Institute | 2021 to 2023 | $1,754,997 | May 1, 2019 | April 30, 2026 | PITTERI, SHARON | reporter.nih.gov |
| Novel Mechanistic Approaches in Prevention, Treatment and Non-Invasive Assessment of Radiation Cystitis in Mice | NIH | National Cancer Institute | 2021 to 2024 | $1,753,498 | June 1, 2021 | May 31, 2026 | KANAI, ANTHONY JOHN | reporter.nih.gov |
| Ethical Multimodal fusion Artificial Intelligence platform (EMAP) to bridge the gap between imaging modalities: Application to prostate cancer diagnosis. | NIH | Office of the Director, National Institutes of Health | 2025 | $1,753,477 | September 15, 2025 | September 14, 2026 | RUSU, MIRABELA | reporter.nih.gov |
| Novel Therapeutic Strategies to Co-Target Undifferentiated Prostate Cancer (PCa) Stem Cells and Bulk PCa Cells | NIH | National Cancer Institute | 2021 to 2025 | $1,753,253 | June 1, 2019 | March 31, 2030 | TANG, DEAN G. | reporter.nih.gov |
| Targeting Polo-Like Kinase 1 in Prostate Cancer to Enhance Therapeutic Efficacy | NIH | National Cancer Institute | 2022 to 2025 | $1,749,738 | July 1, 2022 | June 30, 2027 | LI, ZHIGUO | reporter.nih.gov |
| Clinical Translation of Near Infrared Nerve-Specific Fluorophores for Nerve-sparing Prostatectomy | NIH | National Cancer Institute | 2022 to 2024 | $1,748,403 | July 1, 2022 | June 30, 2025 | BARTH, CONNOR WILLIAM | reporter.nih.gov |
| Oxalate Biodegrading Probiotic for Kidney Stone Prevention | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,742,393 | March 1, 2023 | May 31, 2027 | GEISLER, CHRISTOPH | reporter.nih.gov |
| Targeting allosteric scaffolding functions of Aurora kinase A in cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,740,140 | April 1, 2021 | March 31, 2027 | LEVINSON, NICHOLAS MARK | reporter.nih.gov |
| Detrusor Underactivity as an HCN-mediated Failure of Resilience in Aging | NIH | National Institute on Aging | 2021 to 2023 | $1,739,699 | May 15, 2019 | January 31, 2026 | KUCHEL, GEORGE A | reporter.nih.gov |
| A dyadic exercise approach to prevent declines in physical and mental health in couples during radiation treatment for cancer: a hybrid type I efficacy-implementation trial | NIH | National Cancer Institute | 2023 to 2025 | $1,737,544 | July 1, 2023 | June 30, 2028 | WINTERS-STONE, KERRI M | reporter.nih.gov |
| Oligoribonuclease regulation of cyclic-di-GMP signaling and chronic biofilm infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,736,944 | June 1, 2019 | May 31, 2025 | LEE, VINCENT T | reporter.nih.gov |
| Novel Approaches Targeting B7-H3 in Castration-resistant Prostate Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,734,793 | January 1, 2023 | December 31, 2027 | ZHAO, DI | reporter.nih.gov |
| How is Fullness Sensed in the Urinary Bladder? | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,733,700 | September 1, 2020 | May 31, 2026 | HERRERA, GERALD M. | reporter.nih.gov |
| RET Regulation and Targeting in Neuroendocrine Prostate Cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,732,079 | May 1, 2022 | April 30, 2027 | DRAKE, JUSTIN MICHAEL | reporter.nih.gov |
| Fluid Therapy and Stent Management in Nephrolithiasis, USDRN extension | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2024 | $1,731,992 | September 1, 2016 | August 31, 2025 | MAALOUF, NAIM M | reporter.nih.gov |
| Leveraging PMN immune response to overcome ADT resistance in bone metastatic prostate cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,731,077 | September 1, 2022 | August 31, 2027 | MATHEW, GRINU | reporter.nih.gov |
| Personalized Risk-AdaptIve Surveillance (PRAISE) - Implications of Algorithmic Bias | NIH | National Cancer Institute | 2021 to 2024 | $1,727,788 | September 1, 2018 | August 31, 2026 | BANSAL, AASTHAA | reporter.nih.gov |
| Early life bladder inflammatory events in female mice lead to subsequent LUTS in adulthood | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,726,803 | May 1, 2023 | February 28, 2027 | ZDERIC, STEPHEN ANTHONY | reporter.nih.gov |
| MAOA and AR Reciprocal Crosstalk in Prostate Cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,725,441 | January 1, 2019 | December 31, 2025 | WU, BOYANG | reporter.nih.gov |
| Parp Function in Prostate Cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,722,423 | March 1, 2017 | February 29, 2028 | PASCHAL, BRYCE | reporter.nih.gov |
| MRI Imaging and Biomarkers for Early Detection of Aggressive Prostate Cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,720,463 | September 16, 2019 | August 31, 2025 | POLLACK, ALAN | reporter.nih.gov |
| De-implementation of low value castration for men with prostate cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,718,667 | January 16, 2018 | December 31, 2024 | SAINI, SAMEER DEV | reporter.nih.gov |
| Regenerative therapy for stress urinary incontinence and pelvic floor disorder | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,713,012 | April 1, 2020 | September 30, 2024 | LUE, TOM F | reporter.nih.gov |
| A preconception cohort study of air pollution, fertility, and miscarriage | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $1,711,178 | July 1, 2018 | March 31, 2030 | WESSELINK, AMELIA KENT | reporter.nih.gov |
| Improved Detection of Prostate Cancer with Nanoparticle-based Ultrasound Contrast Agents Targeted to PSMA | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2025 | $1,708,848 | December 15, 2017 | January 31, 2028 | EXNER, AGATA A | reporter.nih.gov |
| Novel roles for urothelium during urinary tract obstruction | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,708,074 | June 11, 2020 | March 31, 2026 | BECKNELL, BRIAN | reporter.nih.gov |
| The Impact of Aging on Prostate Cancer with Age-Related Disruption of Th17/Treg Axis | NIH | National Cancer Institute | 2021 to 2025 | $1,707,208 | January 1, 2021 | December 31, 2026 | ZHANG, QIUYANG | reporter.nih.gov |
| Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors (iLIVE) | NIH | National Cancer Institute | 2023 to 2025 | $1,705,585 | June 22, 2023 | May 31, 2028 | WINTERS-STONE, KERRI M | reporter.nih.gov |
| Development of microparticle-based topical treatments for treating erectile dysfunction in patients refractory to oral PDE5 inhibitors | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $1,705,226 | July 19, 2021 | March 31, 2025 | DRAGANSKI, ANDREW R | reporter.nih.gov |
| The Radium-223 Combination Therapy Space; Improving Response and Clarifying Toxicities | NIH | National Cancer Institute | 2021 to 2024 | $1,701,190 | March 1, 2020 | February 28, 2026 | THOREK, DANIEL LYNDON JAFFE | reporter.nih.gov |
| Transcriptional-translational conflict in bladder epithelial homeostasis and cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,697,731 | January 1, 2023 | December 31, 2027 | HSIEH, ANDREW CALEB | reporter.nih.gov |
| Novel Pathways in the Control of Lineage Plasticity in Neuroendocrine Prostate Cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,691,636 | May 1, 2020 | October 31, 2025 | DIAZ MECO CONDE, MARIA TERESA | reporter.nih.gov |
| Determine the Microphthalmia Transcription Factor (MITF)-regulated cell rewiring mechanisms in lethal prostate cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,690,924 | February 3, 2022 | June 30, 2027 | DOMINGO-DOMENECH, JOSEP MARIA | reporter.nih.gov |
| Centrosome instability as a mechanism to promote localized prostate cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,690,509 | August 22, 2019 | July 31, 2025 | ROGERS, GREGORY CHARLES | reporter.nih.gov |
| Molecular and immune drivers of immunotherapy responsiveness in prostate cancer | NIH | National Cancer Institute | 2021 to 2022 | $1,689,999 | September 19, 2018 | August 31, 2023 | VAN ALLEN, ELIEZER M | reporter.nih.gov |
| The role of the female and male reproductive microenvironment in fertility fitness | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2025 | $1,689,063 | August 1, 2023 | April 30, 2028 | FARR ZUEND, CHRISTINA | reporter.nih.gov |
| Sacral neuromodulation for the management of chronic pelvic pain | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,689,002 | September 20, 2023 | July 31, 2028 | PETERS, KENNETH M | reporter.nih.gov |
| A Novel Therapeutic that Harnesses Microtubules to Promote Cavernous Nerve Regeneration after Radical Prostatectomy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $1,686,452 | September 15, 2018 | August 31, 2024 | BAKER, LISA ANN | reporter.nih.gov |
| Activating Peripheral Glia to Relieve Visceral Pain in Animal Models of Urological Chronic Pelvic Pain Syndrome (UCPPS) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,682,164 | July 19, 2021 | May 31, 2026 | XIE, XIAOQIAO | reporter.nih.gov |
| Genetic analysis of mechanisms of chlamydial immune evasion | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,680,687 | February 1, 2012 | March 31, 2025 | NELSON, DAVID EMMET | reporter.nih.gov |
| Multidimensional analyses to improve PSMA-RPT efficacy in mCRPC | NIH | National Cancer Institute | 2023 to 2025 | $1,679,715 | July 12, 2023 | March 31, 2028 | CZERNIN, JOHANNES | reporter.nih.gov |
| Harnessing Behavior to Decrease Urinary Stone Disease Morbidity Research Project | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2024 | $1,678,692 | September 1, 2016 | August 31, 2025 | TASIAN, GREGORY EDWARD | reporter.nih.gov |
| Tactile and ultrasound imaging fusion for functional assessment of the female pelvic floor | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $1,678,556 | February 8, 2019 | August 31, 2024 | EGOROV, VLADIMIR | reporter.nih.gov |
| Solid-state nanopores and silicon nanomembranes for ultrasensitive protein biomarker detection | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $1,678,043 | June 15, 2021 | March 31, 2026 | MCGRATH, JAMES L | reporter.nih.gov |
| Recovery Support for Bladder CA Patients and Caregivers: A Multimodal Approach | NIH | National Cancer Institute | 2021 to 2023 | $1,676,493 | July 1, 2018 | December 31, 2024 | DIEFENBACH, MICHAEL A | reporter.nih.gov |
| Investigating lineage plasticity in castration-resistant prostate cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,673,048 | July 1, 2020 | June 30, 2025 | SHEN, MICHAEL M. | reporter.nih.gov |
| Elucidating Chemical Features that Block or Facilitate Passage across the Blood-Testis and/or Blood-Epidydimal Barriers in Mice | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2024 | $1,672,438 | April 6, 2020 | March 31, 2026 | LI, FENG | reporter.nih.gov |
| Revealing Stochastic Switches in Bacteria | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,668,929 | September 15, 2011 | August 31, 2027 | KUSSELL, EDO L | reporter.nih.gov |
| Stromal senescence in lethal prostate cancer: a novel target for prognosis and therapy | NIH | National Cancer Institute | 2021 to 2025 | $1,668,272 | January 1, 2021 | December 31, 2025 | PLATZ, ELIZABETH A. | reporter.nih.gov |
| Singlet Oxygen-cleavable Prodrugs for Treating Non-Muscle Invasive Bladder Cancers | NIH | National Cancer Institute | 2022 to 2025 | $1,665,189 | July 13, 2022 | June 30, 2027 | YOU, YOUNGJAE | reporter.nih.gov |
| The telomere biomarker as a tool to inform decision-making for aggressive salvage therapy in men with rising PSA post prostatectomy | NIH | National Cancer Institute | 2023 to 2025 | $1,663,456 | August 22, 2023 | July 31, 2027 | MEEKER, ALAN KEITH | reporter.nih.gov |
| Mechanisms of contractile dysfunction in the obstructed bladder: Role of desmin and vimentin | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,656,768 | September 15, 2022 | May 31, 2027 | ETTICKAN, BOOPATHI | reporter.nih.gov |
| Targeting chemoresistant prostate cancer with novel EED inhibitors | NIH | National Cancer Institute | 2022 to 2025 | $1,655,250 | April 1, 2022 | March 31, 2028 | WU, DAQING | reporter.nih.gov |
| Novel Degraders of the Androgen Receptor (AR) and AR Splice Variants (AR-SVs) | NIH | National Cancer Institute | 2021 to 2023 | $1,653,777 | February 1, 2019 | January 31, 2025 | NARAYANAN, RAMESH | reporter.nih.gov |
| Gut-kidney axis in enteric hyperoxaluria | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,651,590 | September 6, 2021 | May 31, 2027 | NAZZAL, LAMA | reporter.nih.gov |
Organizations
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 867 | $499,898,954 | 0 | $0 |
| 2024 | 1,008 | $483,906,906 | 0 | $0 |
| 2023 | 1,026 | $492,542,063 | 0 | $0 |
| 2022 | 987 | $474,574,396 | 0 | $0 |
| 2021 | 1,001 | $470,649,255 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.